

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089022 A1

(51) International Patent Classification⁷: **A61L 27/24**, (74) Agents: **LADWIG, Glenn, P. et al.**; Saliwanchik, Lloyd & Saliwanchik, 2421 N.W. 41st Street, Suite A-1, Gainesville, FL 32606-6669 (US).

(21) International Application Number: **PCT/US03/12076**

(22) International Filing Date: 18 April 2003 (18.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/373,801 18 April 2002 (18.04.2002) US

(71) Applicant (*for all designated States except US*): **UNIVERSITY OF FLORIDA [US/US]**; 223 Grinter Hall, Gainesville, FL 32611-5500 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **GOWER, Laurie, B. [US/US]**; 2270 N.W. 21st Ave, Gainesville, FL 32605 (US). **OLSZTA, Matthew, J. [US/US]**; 2330 S.W. Williston Rd. Apt. 2315, Gainesville, FL 32608 (US). **DOUGLAS, Elliot, P. [US/US]**; 3405 N.W. 60th Lane, Gainesville, FL 32653 (US). **MUNISAMY, Sivakumar [IN/US]**; 988 S.W. 16th Avenue, Gainesville, FL 32601-8432 (US). **WHEELER, Donna, L. [US/US]**; 709 Gilgalad Way, Fort Collins, CO 80526 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1

WO 03/089022

(54) Title: BIOMIMETIC ORGANIC/INORGANIC COMPOSITES, PROCESSES FOR THEIR PRODUCTION, AND METHODS OF USE

(57) Abstract: The subject invention concerns a composite comprising an organic fluid-swellable matrix, such as collagen, and mineral phase, such as calcium carbonate or phosphate mineral phase, for use as a biomimetic of bone. In another aspect, the subject invention concerns a process for making a composite involving the inclusion of acidic polymers to a supersaturated mineralizing solution, in order to induce an amorphous liquid-phase precursor to the inorganic mineral, which is then absorbed (pulled by capillary action) into the interstices of the organic matrix, and subsequently mineralizes via solidification and crystallization of the precursor phase. The present invention further concerns a method of treating a patient suffering from a bone defect by applying a biomimetic composite to the bone defect site.

DESCRIPTIONBiomimetic Organic/Inorganic Composites, Processes for Their Production, and Methods of Use

The subject invention was made with government support under a research project supported by National Science Foundation Grant No. ECS-9986333. The government has certain rights in this invention.

Cross-Reference to Related Application

This application claims the benefit of U.S. Provisional Application No. 60/373,801, filed April 18, 2002, which is hereby incorporated by reference in its entirety, including all figures, tables, and drawings.

Background of the Invention

[0001] Synthetic bone graft material made to closely resemble natural bone would be a useful replacement for natural bone. Acceptable synthetic bone can avoid the problem of availability and harvesting of autogenous bone and the risks and complications associated with allograft bone, such as risks of infection, disease, and viral transmission.

[0002] Natural bone is a composite material consisting of both water and organic and inorganic solid phases. Bone has a hard structure because its organic extracellular collagenous matrix is impregnated with inorganic crystals, principally hydroxyapatite ($\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$). Calcium and phosphate account for roughly 65% to 70% of the bone's dry weight. Collagen fibers compose approximately 95% of the extracellular matrix and account for 25% to 30% of the dry weight of bone. The organic material gives bone its flexibility and resilience, while the inorganic material gives bone its strength and rigidity (modulus), and the organization of the two phases provides a high degree of toughness to the composite. A thorough review of bone structure from the angstrom level (mineral crystal) to the micron level (lamellae) has been presented (Weiner, S. *et al.* [1992] *FASEB*, 6:879-885).

[0003] Surrounding the mineralized collagen fibers is a ground substance consisting of protein-polysaccharides, or glycosaminoglycans, primarily in the form of proteoglycan macromolecules. The glycosaminoglycans serve to cement together the various layers of mineralized collagen fibers. The individual collagen molecules self-assemble to form triple helices, which assemble into collagen fibrils, which then assemble into microscopic fibers. Within the packing of the collagen fibrils/fibers are distinct gaps, sometimes called hole zones. These hole zones are created by the staggered arrangement of tropocollagen molecules (triple helical rods), which leads to periodicity of the hole and overlap zones. Various models have been proposed where these hole zones are completely isolated from each other, or are contiguous and together form a groove. Within these hole zones, mineral crystals form. The mineral crystals in final form nucleate and grow within the fibrils (intrafibrillar mineralization), as well as into the interstitial spaces (interfibrillar mineralization) (Landis, W.J. *et al.* [1993] *J. Struct. Biol.* 110:39-54). The mineral crystals in final form are a carbonated apatite mineral (dahllite), but initially may form as an amorphous calcium phosphate phase, which then transforms into the apatite (or possibly via an octacalcium phosphate precursor, which naturally forms plates). The apatite platelets of bone are of nanoscopic dimensions (only a few unit cells thick), and are densely packed into the type I collagen fibrils due to the intrafibrillar mineralization mechanism, and are well oriented with their *c*-axis parallel to the long axis of the collagen fibrils. Because of the nature of the packing, the orientation of the collagen fibrils will determine the orientation of the mineral crystals (Martin, R.B. *et al.* [1998] "Skeletal Tissue Mechanics", Springer-Verlag Publishers, New York, N.Y.).

[0004] There are numerous biocompatible artificial bone substitutes currently on the market. Of these substitutes, none successfully mimics the composite or microstructure of bone. For example, man-made ceramic composites have some of the desired properties of natural bone (such as matching of modulus), but are notoriously brittle and prone to cracking. By contrast, biological ceramics like bone and teeth resist cracking, with a high toughness and stiffness. It is the nanostructured architecture that leads to mechanical properties that are unique to bone, which are not readily duplicated by polymers (which are not strong or stiff enough), or ceramics (which are brittle and lack toughness, and usually not bioresorbable). These mechanical properties are important because of the body's natural repair processes, in which bone is a living tissue and the cells respond according to the stresses they sense in their surrounding tissue (according to Wolf's

Law). If an implant material has too high of a modulus (stiffness), the cells tend to resorb the surrounding bone due to the phenomenon of stress shielding (the stiffer material carries more of the load than the surrounding bone).

[0005] A logical choice of materials for a synthetic bone substitute would be a collagen-hydroxyapatite composite; indeed, many have attempted to mineralize collagen *in vitro*, but the preparation of such a composite has been limited by the ability to achieve the high mineral loading that is attained biologically by intrafibrillar mineralization. An associated periodic contrast pattern is commonly observed by transmission electron microscopy (TEM) of collagen fibers (Carter, J.G. [1990] *Skeletal Biomineralization: Patterns, Processes and Evolutionary Trends*, Volume 1, Van Nostrand Reinhold Publishers, New York, N.Y.; Hodge, A.J. *et al.* [1963] "Recent studies with the electron microscope on ordered aggregates of the tropocollagen molecule", in *Aspects of Protein Structure*, Ramachandran, G.N. (ed.), pp. 289-300, Academic Press, London, England; Katz, E.P. *et al.* [1989] *Connect. Tissue Res.*, 21:49-159). From tomographic imaging of naturally mineralizing turkey tendon (which is considered a model of secondary bone formation), there is evidence that the hydroxyapatite crystals first appear within the hole zones of collagen (described as inorganic substance in bands (ISBs)), and then spread throughout the fibrils, leading to the array of iso-oriented nanocrystals of highly organized hydroxyapatite [HAP] embedded within the organic matrix (Landis, W.J. *et al.* [1993] *Structural Biology*, 110:39-54; Landis, W.J. *et al.* [1991] *Connect. Tissue Res.*, 25:181-196; Bonnuci, E. *Calcification in Biological Systems* [1992] CRC Press Boca Raton, FL).

[0006] From a materials engineering perspective, the nanostructure of bone is intriguing and can be difficult to define. For example, it is not clear whether bone is more accurately characterized as a polymer-fiber-reinforced ceramic-matrix composite or a ceramic-nanoparticle-reinforced polymer-matrix composite. The two phases are so intimately linked that the mechanical properties are distinctly different than ceramics or polymers, and therefore are difficult to reproduce. To date, scientists do not have a complete understanding of how bone is formed, even at this most basic level of structure. However, it is likely that the nanostructured architecture plays a role in the toughness of bone. Obviously, cellular control is important in biomineralization, and in the case of bone, helps to build its hierarchical structure (*i.e.*, lamellae and osteons), but even the physicochemical mechanism for generating this nano-architecture has not been elucidated. Because intrafibrillar mineralization does not occur simply by attempting to

crystallize collagen *in vitro* using supersaturated solutions of HAP (crystals only nucleate heterogeneously on the surface of the collagen fibers), it is generally assumed that nucleating proteins must be present within the gaps of the collagen fibrils.

[0007] It is understood within the biominerization community that acidic proteins can act as inhibitors to crystal nucleation or growth (Addadi, L. *et al.* [1987] *Proc. Natl. Acad. Sci. USA*, 84:2732-2736; Addadi, L. *et al.* [1992] *Angew. Chem. Int. Ed. Engl.* 31:153-169; Mann, S. *et al.* [1983] *Structure and Bonding*, 54:125-174; Mann, S. *et al.* [1989] "Crystallochemical Strategies in Biominerization" in *Biominerization-Chemical and Biochemical Perspectives*. Mann, S., Webb, J., and Williams, R.J.P. (eds.), 33-62 (VCH Publishers, N.Y., New York)). In the case of crystal growth, it has been shown that selective inhibition of growth along stereospecific crystallographic planes can lead to a change in crystal morphology (Addadi, L. *et al.* *Angew. Chem. Int. Ed. Engl.*, 24:466-485). Patterns of calcite crystallization can be modified for growth in distinct patterns (Aizenberg, J., [2000] *J. Crystal Growth*, 211:143-8). In at least a few cases, acidic proteins have been shown to promote crystal nucleation (Addadi, L. *et al.* [1987] *Proc. Natl. Acad. Sci. USA*, 84:2732-2736; Greenfield, E.M. *et al.* [1984] *Amer. Zool.*, 24:925-932). It has also been shown that if the inhibitory action of a macromolecule is not complete, certain conditions lead to the induction (stabilization) of an amorphous liquid-phase precursor (Gower, L.B. *et al.* [2000] *J. Crystal Growth*, 210(4):719-734), which can have a profound consequence on crystal morphology since transformation of an amorphous precursor does not proceed via the same mechanism as traditional solution crystal growth (Mann, S. *et al.* [1989] "Crystallochemical Strategies in Biominerization" in *Biominerization-Chemical and Biochemical Perspectives*. Mann, S., Webb, J., and Williams, R.J.P. (eds.), 33-62 (VCH Publishers, N.Y., New York)). Certain features of this polymer-induced liquid-precursor (PILP) process suggest that this mechanism may occur during morphogenesis of calcium carbonate biominerals in invertebrates (Gower, L.A. [1997] "The Influence of Polyaspartate Additive on the Growth and Morphology of Calcium Carbonate Crystals," Doctoral Thesis, Department of Polymer Science and Engineering, University of Massachusetts at Amherst, 1-119).

[0008] It would be desirable to have the capability to synthetically prepare a bone graft substitute that matches both the chemical and mechanical properties of bone. Such a material would be both load-bearing (with the appropriate modulus, strength, and toughness), yet bioresorbable to allow for the body's own tissue repair process to regenerate natural bone.

Brief Summary of the Invention

[0009] The subject invention concerns an organic/inorganic composite comprising an inorganic mineral phase deposited onto and within an organic matrix, which is useful as a biomimetic substitute for bone and other tissues. The organic matrix is fluid-swellable and is penetrated by the inorganic mineral phase while the inorganic mineral phase is in the form of an amorphous polymer-induced liquid-precursor (PILP) phase. Optionally, while in the liquid-precursor phase, the inorganic mineral penetrates and saturates the matrix, which can cause the matrix to swell. The fluid-swellable matrix can also include interstitial spaces and pores within the matrix structure, having the inorganic mineral deposited therein.

[0010] Preferably, the fluid-swellable matrix of the composite is a longitudinally aligned fibrous material, with the inorganic mineral deposited intrafibrillarily within the matrix. More preferably, the organic substrate is collagen and the inorganic mineral is calcium phosphate, calcium carbonate, or a mixture thereof, wherein the inorganic mineral is deposited intrafibrillarily within the collagen substrate. Examples of suitable calcium-containing inorganic minerals that can be used for the organic/inorganic composites of the invention include, but are not limited to, calcium phosphate, calcium carbonate, hydroxyapatite, strontium carbonate, calcium sulfate, calcium oxalate, calcium oxide, magnesium-bearing calcium carbonate or phosphate, calcium sulfate, calcium oxalate, and magnesium-bearing calcium carbonate or phosphate, or any polymorphs of these minerals.

[0011] In another aspect, the subject invention concerns a process for making the composite described herein involving the inclusion of short-chained acidic polymers to a supersaturated mineralizing solution, in order to induce an amorphous liquid-phase precursor to the mineral, which is then pulled by capillary action into interstices of the organic matrix (thus infiltrating the organic substrate), and subsequently mineralizes via solidification and crystallization of the precursor phase.

[0012] By using a PILP phase, the process of the present invention permits superior infiltration of an inorganic mineral phase (such as calcium phosphate or calcium carbonate) into an organic matrix (such as collagen), closely mimicking the structure of natural bone, which is a composite of collagen and calcium phosphate. In addition to being highly mineralized, the organic/inorganic composite of the present invention is biocompatible, bioresorbable, and

capable of load-bearing applications, such as use as a bone-graft substitute in critical-sized osseous defects, or joint replacement (such as artificial hip replacement).

[0013] The organic substrate that is mineralized according to the process of the subject invention preferably comprises collagen fibrils. However, other fluid-swellable materials, such as sponges composed of bioresorbable polymers (such as hyaluronic acid, polyglycolic acid (PLGA), or poly(L-lactic acid) (PLLA)), can serve as the organic substrate.

[0014] The present invention further concerns a method of treating a patient having a bone defect by applying a composite described herein to the site of the bone defect.

Brief Description of Drawings

[0015] Figures 1A-1B show scanning electron micrographs (SEMs) of “fibrous” biomineral morphologies that occur in the teeth of invertebrates and vertebrates. Figure 1A shows that the rib region of a sea urchin tooth (*Arbacia tribuloides*) contains magnesium bearing calcium carbonate “rods”, 5-7 μ m in diameter, embedded in an amorphous CaCO₃ matrix. Figure 1B shows that the ultrastructure of enamel from a rat incisor is more complex because it is “woven” into a cross-ply architecture by the ameloblast cells. Of relevance is the non-equilibrium morphology of the crystals, which in the vertebrates are polycrystalline bundles of HAP, rather than single-crystalline calcite rods, as in the urchin tooth. This further supports the assertion that the PILP process plays a fundamental role in the morphogenesis of biominerals, both in the vertebrates and invertebrates, as seen in the fibrous mineral morphologies produced by the PILP process shown in Figures 3A-3D.

[0016] Figures 2A-2C show SEM, transmission electron microscopy (TEM) and energy dispersive spectroscopy (EDS) analyses of calcium phosphate PILP phase prepared with CaCl₂, poly(vinyl phosphonic acid),(PVPA) and polymer-assisted solution-phase (such as polyaspartic acid: PASP) additives. Figure 2A shows a SEM micrograph of solidified precursor droplets. The droplets appear to have only partially coalesced and may not have been as fluidic as is typical of the CaCO₃ PILP phase. Figure 2B shows a TEM micrograph of early stage solidified PILP droplets (average size \approx 200nm). Light scattering studies have shown that the PILP droplets (for CaCO₃) start out approximately 100 nm in diameter and grow steadily until they reach a size of a couple of microns (when they become visible by optical microscopy). Figure 2C shows an EDS of the sample shown in Figure 2A confirming that the PILP phase is

composed of calcium and phosphate. The small C and O peaks suggest that carbonate may also be present, which is difficult to eliminate due to CO₂ in the atmosphere.

[0017] Figures 3A-3D show SEMs of fibrous CaCO₃ crystals formed *in vitro* using acidic polymeric additives. Fibrous morphologies have also been produced in the carbonate salts of calcium, barium, and strontium, but at this time, only the CaCO₃ system has been examined *in situ* to determine if the fibers result from extrusion of a precursor phase. Figure 3A shows an optical micrograph with cross-polarized light, making it evident that the fibrous structures are birefringent and single-crystalline (they exhibit a uniform extinction direction). Figure 3B shows the overall aggregate and fibrous extensions in an optical micrograph, which was taken with insertion of the 1st-order red waveplate to reduce glare. It can be seen that some of the fibers are straight (bottom aggregate), while some are “squiggly” (top aggregate). The uniform retardation color of the fibers also demonstrates the single-crystalline nature of the fibers. A few single-crystalline “drops” are also present (*e.g.* the blue crystal at the top edge). Figures 3C and 3D, two SEM micrographs, show that the fibers emanate from a centralized aggregate of ill-defined globular shape, and the fibers are relatively uniform in cross-section with a diameter of approximately 0.5 μm - 1 μm, and have been observed to exhibit nanosized dimensions as well. Figure 3D shows that the fluidic nature of the precursor is apparent in these solidified products because of the small fiber which is bent and appears to be draped across a larger fiber (at the center), and was not constrained to grow along a crystallographically defined direction.

[0018] Figures 4A and 4B show SEMs of PILP-mineralized bovine collagen. The mineral precipitated predominantly as a coating on the fibers, but in some regions, as illustrated in Figures 4A and 4B, isolated platy tablets deposited along the fiber in a banded pattern. These bands of CaCO₃ tablets (composition verified by EDS) are perpendicular to the long axis of the collagen fiber (indicated with an arrow), and appear to be associated with the topography of the fiber (perhaps nucleated on the crimps).

[0019] Figures 5A-5D show SEMs of mineralized CELLAGEN sponge. Figure 5A shows that the sponge, as received (not mineralized), consists of an isotropic mesh of type-I collagen fibers. Figure 5B shows that the control reaction, in which collagen was mineralized with CaCO₃ without the addition of polymer, shows large rhombohedral crystals of calcite which nucleated heterogeneously on the collagen. Figure 5C shows that when the sponge was mineralized using the PILP process, very different morphologies were formed, in which patchy,

thick calcitic films were deposited. Figure 5D shows that at higher magnification, it can be seen that the thick film is actually composed of collagen fibers encased in mineral. Because the encasing mineral is solid, it does not dehydrate to as large an extent as the surrounding matrix of pure collagen upon vacuum treatment for SEM analysis; therefore, the film-like composite is much thicker than the surrounding non-mineralized region, and appears as a step. It is also evident that the mineral provides some protection against beam damage, which was not the case for the un-mineralized region, in which a crack formed just below the mineralized patch. Note-the speckled appearance of the mineral is typical of PILP products, in which some precursor droplets do not fully coalesce to form smooth films (Gower, L.B. and D.J. Odom *J. Crystal Growth* 2000, 210(4):719-734; Gower, L.A. and D.A. Tirrell *J. Crystal Growth* 1998, 191(1-2):153-160).

[0020] Figures 6A and 6B show SEMs with banding patterns on mineralized collagens. Figure 6A shows that this bovine collagen fiber was only partly mineralized, yet the fiber did not densify upon dehydration, suggesting that some of the mineral had penetrated into the fiber, which holds the remaining non-mineralized sub-fibers in place (arrow). In both the bovine collagen and CELLAGEN sponge, banding patterns became apparent after mineralization, which are not observed in the fibers as received (see Figure 5A). In this case, however, the bands are not composed of tablets, but rather by a slight blebbing of the mineral coating (bottom right of fiber). The spacing of the bands is much smaller, at a sub-micron size scale (unlike the dimensions of the collagen crimp shown for the tablets in Figure 4). Figure 6B shows that blebbing of the small collagen sub-fibers in the CELLAGEN sponge is very pronounced in this particular region, to the point of having a disc-like appearance, in which the discs are oriented perpendicular to the long axis of the fibers. The banding pattern here is robust enough to measure; the bands occur at approximately every 380 nm, which is approximately six times the 64 nm spacing of type I collagen.

[0021] Figures 7A-7D show SEM micrographs of DAVOL Ultrafoam sponges under different mineralization conditions. Figure 7A shows DAVOL Ultrafoam, no treatment, as received showing pore size on the order of 2-100 μm in diameter. Figure 7B shows DAVOL Ultrafoam mineralized in the absence of polymeric additives, in which 20 μm diameter calcite rhombohedrals nucleated on the surface of the sponge. Figure 7C shows a partially mineralized section of DAVOL Ultrafoam mineralized in the presence of PAA (5100 MW, ALDRICH).

Figure 7D shows a fully mineralized section of DAVOL Ultrafoam mineralized in the presence of PAA (5100 MW, ALDRICH).

[0022] Figures 8A-8C show calcium phosphate mineralized CELLAGEN sponge etched with 0.1 N HCl for 15 minutes to remove surface encapsulating mineral. Results are similar to CELLAGEN sponge mineralized with CaCO_3 .

[0023] Figures 9A-9D show TEM, Bright Field (BF) and electron diffraction analyses of mineralized CELLAGEN experiments. Figure 10A shows a BF image of a CELLAGEN sponge stained with 1% phosphotungstic acid in 0.1M PBS. A 67-70 nm characteristic collagen banding pattern is observed. Figure 10B shows a diffraction pattern of stained collagen. Observed pattern is similar to transmitted beam pattern, as there are no diffraction spots. Figure 10C shows a BF image of CELLAGEN sample mineralized with CaP mineral through the PILP mechanism. Notice the 50-70 nm round particles around and in the collagen fibril (arrows). Bar = 100 nm. Figure 10D shows a typical diffraction pattern of mineralized collagen fibril. Notice strong diffraction peaks in direction of c-axis of collagen fibril.

[0024] Figure 10 shows X-ray diffraction (XRD) analysis, with Line A showing the diffraction pattern of dehydrated collagen sponge held in distilled water for three days, Line B showing the diffraction pattern of collagen sponge mineralized without polymer for three days in a supersaturated CaCO_3 solution, and Line C showing the diffraction pattern of collagen sponge mineralized for three days in a supersaturated solution of CaCO_3 containing acidic polymers. The characteristic calcitic peaks on Line B and Line C are in the same position. The peaks in Line C are much broader than those in Line B, suggesting that either there is strain in the crystals, or the crystals are of much smaller size as compared to those in Line B (Cullity, B.D., "Elements of X-ray Diffraction" [2001] Addison-Wesley Longman, N.Y.)

[0025] Figure 11 shows an SEM of a SCOTCH BRITE sponge that has not been introduced to mineralizing solutions. This household sponge has micropores on the order of 0.75 microns – 2.0 microns in diameter.

[0026] Figure 12 shows an SEM of a CELLAGEN sponge (reconstituted bovine Type-I collagen) that has been mineralized using the process of the subject invention. The fibers are collagen and the mounds are collagen fibers coated in calcium carbonate.

[0027] Figure 13 shows an SEM of a SCOTCH BRITE sponge that has been mineralized using the process of the subject invention. The sponge has been coated with non-equilibrium morphology calcium carbonate, thus clogging some of the pores.

[0028] Figure 14 is an SEM of a CELLAGEN sponge (as described in Figure 13) that has been mineralized using the process of the subject invention. The sample was mineralized four times. Specifically, the sample was run for three days and the mineralizing solution was subsequently refreshed (the equivalent of one mineralization). The sample was then placed in a 0.1N HCl solution to etch away the surface coating of calcium carbonate. The large bundle of fibers in the middle of the picture shows how the whole bundle may have been coated (hence, the end which still seems to be coated) and the acid etch preferentially left behind bands of calcium carbonate.

[0029] Figure 15 shows an SEM of a CELLAGEN sponge (as described in Figure 13) that has been mineralized using the process of the subject invention. The sample was mineralized five times. Specifically, the sample was run for three days and the mineralization solution was subsequently refreshed (the equivalent of one mineralization). The sample was then placed in a 0.1 N HCl solution to etch away the surface coating of calcium carbonate. Again, all of the fibers appear to have been coated and the acid etch preferentially etched away the excess calcium carbonate, leaving behind banded calcium carbonate that was protected from the etchant by the surrounding collagen fiber.

[0030] Figure 16 shows an SEM of a CELLAGEN sponge (as described in Figure 13) that has been mineralized using the process of the subject invention. The sample was mineralized five times. Specifically, the sample was run for three days and the mineralization solution was subsequently refreshed (the equivalent of one mineralization). The sample was then placed in a 10% bleach solution to etch away the organic material, specifically collagen. With the collagen removed, it can be seen that the calcium carbonate that remains had totally infiltrated the collagen (the perpendicular bands of mineral span completely across the pre-existing fibers).

[0031] Figures 17A and 17B shows SEM images of mineralized CELLAGEN scaffolds (with polymer) after exposure to mineralized solution. Figure 17A shows osteoblasts adhered to mineralized scaffold at a magnification of 150x. Figure 17B shows an adhered osteoblast producing mineralization nodules at a magnification of 1000x.

[0032] Figure 18 shows the number of cells adhering to the three different scaffold types after a three and a half hour exposure. The three types of scaffolds include A) unmineralized with 9,658 cells; B) mineralized without polymer with 18,223 cells; and C) mineralized with polymer with 20,296 cells.

[0033] Figures 19A-20E show materials and methods for producing individually mineralized films of the present invention.

[0034] Figures 20A-20C show mineralized films of the present invention, which can be adhered to one another in an alternating orientation, to form a cross-ply architecture.

Detailed Disclosure of the Invention

[0035] The composite of the present invention comprises an organic substrate and an inorganic mineral phase, useful as a biomimetic material of bone or other hard tissue. Thus, the composite of the subject invention is an organic/inorganic composite that is highly mineralized, with its organic and inorganic components intimately associated in a manner mimicking the structure of natural bone. The organic substrate is composed of a fluid-swellable matrix, which is penetrated by the inorganic mineral phase while the inorganic mineral is in the form of a polymer-induced liquid-precursor phase (PILP) that subsequently solidifies.

[0036] Optionally, while in the liquid precursor phase, the inorganic mineral penetrates and saturates the matrix, which can cause the matrix to swell. The fluid-swellable matrix can also have interstitial spaces and pores, having the inorganic mineral deposited therein.

[0037] The organic substrate that is mineralized with an inorganic phase according to the process of the subject invention is preferably fibrous. In one embodiment, the fibrous organic substrate comprises collagen fibrils as a parallel fibered matrix. In one embodiment, the fibrous organic substrate is collagen. However, other fluid-swellable materials, such as sponges composed of bioresorbable polymers (such as hyaluronic acid, polyglycolic acid (PLGA), or poly(L-lactic acid) (PLLA)) can serve as the organic substrate, instead of collagen, or in addition to collagen. The inorganic phase is preferably calcium phosphate, calcium carbonate, or a mixture thereof. Examples of suitable calcium-containing inorganic minerals that can be used for the organic/inorganic composites of the invention include, but are not limited to, calcium phosphate, calcium carbonate, hydroxyapatite, strontium carbonate, and calcium sulfate, calcium

oxalate, calcium oxide, magnesium-bearing calcium carbonate or phosphate, or any polymorphs of these minerals.

[0038] The composite of the subject invention has similar mechanical, chemical, and biological properties to normal human bone tissue; thus, representing a biomimetic of bone (emulating the structure and mechanisms of the biological tissue), without the shortcomings of current artificial bone-replacement materials. For example, once solidified and crystallized, the inorganic mineral phase of the composite of the present invention lacks the facets typically present in other artificially mineralized collagen composites. Therefore, the composite of the present invention more closely resembles the patterns of mineral deposition found in nature, such as in human bone. In addition, the composite of the subject invention does not have the disadvantages associated with using donor tissue, such as disease transfer, rejection, unknown resorption rate, and scarcity.

[0039] In another aspect, the subject invention concerns a process for making the composite described herein involving the inclusion of one or more acidic polymers to a supersaturated mineralizing solution, in order to induce an amorphous liquid-phase precursor to the mineral, which is then absorbed by capillary action into the fluid-swellable matrix of the organic substrate, and subsequently solidifies and crystallizes into the mineral phase. Preferably, the acidic polymer is a short-chained acidic polymer. The process of the subject invention, which uses a polymer-induced liquid precursor (PILP), permits superior infiltration of the mineral phase into the organic phase, such that the mineral phase is intimately associated with the organic matrix. In composites having an organic matrix comprising fibrils, the mineral phase can be associated with the organic matrix to the extent that nanocrystals are embedded within the interstices of the fibrils. Thus, as used herein, the term “liquid-precursor” refers to an inorganic mineral phase that is sufficiently fluid to infiltrate, or be absorbed by, the fluid-swellable matrix.

[0040] The process of the subject invention comprises contacting an acidic polymer, such as poly-L-aspartic acid and/or polyacrylic acid, with a mineralizing solution of a calcium-containing mineral, thereby forming a liquid-phase mineral precursor; and contacting an organic substrate with the liquid-phase mineral precursor, wherein the organic substrate is collagen or another polymeric, fluid-swellable material, (such as hyaluronic acid, polyglycolic acid (PLGA), or poly(L-lactic acid) (PLLA)). The calcium-containing mineralizing solution can contain, for example, calcium salt, calcium chloride, and/or calcium phosphate, or other calcium-containing

minerals. The liquid-phase mineral precursor is fluidic and amorphous such that droplets of the precursor are drawn into the organic substrate by capillary action. The droplets coalesce into a continuous coating and are preferentially absorbed into any interstices present within the organic substrate. Advantageously, where the organic substrate is collagen, the liquid-phase mineral precursor is drawn into the gaps and grooves of the collagen fibrils. As used herein, the term "gap" refers to the interstitial space between abutting ends of fibrils. Contiguous gaps among adjacent fibrils are referred to herein as "grooves".

[0041] The polymeric additive stabilizes the amorphous precursor to the mineral that is in the form of a liquid or liquid-like viscosity. Upon solidification of the precursor, non-equilibrium (non-faceted) crystal morphologies are generated that are distinct from the crystals produced by other solution crystallization processes carried out under similar conditions without the polymeric additive. In particular, because of the fluidic nature of the precursor, many of the highly unusual morphologies associated with biominerals (such as biominerals "molded" within vesicular compartments or "extruded" into fibers), can readily be accomplished using the process of the present invention.

[0042] After having coated and infiltrated the organic substrate, the amorphous mineral precursor solidifies and crystallizes, and the overall composite densifies. In the case of collagen, the present inventors have observed that disk-shaped crystals can be left periodically spaced within the fibers at approximately 380 nm intervals, which correlates to approximately six times the natural gap spacing of collagen. Presumably, the gaps have aligned across the fiber to form grooves capable of mineralizing, or the mineral diffuses throughout the interstitial space of the matrix, and is not restricted to just the hole zones. Interstitial space refers to the space between macromolecular chains, or in the case of collagen, the space between the staggered array of tropocollagen rods. Therefore, in the case where calcium carbonate is the inorganic mineral, the result is a nanostructured composite with calcitic nanocrystals embedded within the collagen fibrils, in a similar fashion to natural bone.

[0043] One or more steps of the process of the subject invention can be repeated. Hence, sequential loading of the organic substrate with the inorganic mineral can be carried out, resulting in various degrees of mineralization of the organic substrate. The extent of mineralization can be determined using methods of polymer matrix analysis known to those of ordinary skill in the art, such as thermogravimetric analysis (TGA) and ash fractionation of the

inorganic and organic phases. Preferably, the composite of the subject invention comprises about 25% to about 40% organic matrix (such as collagen or other fluid-swellable material) and about 35% to about 50% mineral phase (such as calcium phosphate, calcium carbonate, or a mixture thereof), by volume. The remaining component (about 10% to about 40%) can be water and non-collagenous (glyco)proteins, for example. More preferably, the composite of the subject invention comprises about 30% to about 34% organic substrate, and about 40% to about 45% mineral phase, by volume. Most preferably, the composite of the subject invention comprises about 32% organic substrate, about 43% mineral phase, and about 25% water, by volume, similar to the composite of natural bone.

[0044] Using a polymer-induced liquid phase precursor, the process and composites of the present invention are distinguishable from known methods for mineralization of reconstituted collagen that yield only equilibrium calcite rhombohedral crystals that nucleate heterogeneously and grow only on the exterior surface of the fibers. Mineralization using the process of the subject invention permits infiltration of the mineral into the matrix structure of the organic substrate, as evidenced by the banding of the collagen fibers, which consists of calcitic disks lying perpendicular to the long axis of the collagen fibers. This banding pattern is somewhat periodic and occurs with a spacing of approximately 250 nm to 300 nm, which roughly corresponds to six times the natural 64 nm spacing of hole zones within biogenic tropocollagen (the spacing is likely disturbed due to reconstitution of the commercial Type-1 collagen; alternatively, the spacing may arise from diffusion-limited exclusion of impurities (e.g., collagen and acidic polymer) during the crystallization process). Without being bound by theory, it is presumed that the PILP mineralization process results from the ion-binding affinities of the short-chained acid polymer in conjunction with water retention and nucleation inhibition, such that a metastable ionic liquid-phase precursor is generated.

[0045] The liquid-phase precursor of the inorganic mineral can be produced using a variety of methods. For example, synthesis of a liquid-phase precursor of calcium carbonate has been described previously (Gower, L.B. and D.J. Odom *J. Crystal Growth* 2000, 210(4):719-734; Gower, L.A. [1997] "The Influence of Polyaspartate Additive on the Growth and Morphology of Calcium Carbonate Crystals," Doctoral Thesis, Department of Polymer Science and Engineering, University of Massachusetts at Amherst, 1-119; Gower, L.A. and D.A. Tirrell *J. Crystal Growth* 1998, 191(1-2):153-160), where the vapor diffusion of the decomposition

products of crushed ammonium carbonate ($(\text{NH}_4)_2\text{CO}_3$) into a solution containing calcium chloride (CaCl_2) and one or more short-chain acidic polymer additives. Alternative methods can be used to gradually raise the supersaturation of the crystallizing solution, including direct addition of a carbonate containing solution to the calcium containing solution; or the escape of carbon dioxide gas from a saturated calcium bicarbonate solution (which produced by bubbling carbon dioxide into an aqueous solution containing the calcium carbonate salt). Supersaturation can also be raised using temperature, pH, or removal of inhibitory species. Similar methods can be used for the calcium phosphate system, although higher temperature (37°) is more favorable for decomposition of ammonium phosphate. In addition, the phosphate counterion can be produced using enzymes that cleave phosphate-containing moieties. According to the mineralization process of the subject invention, the organic substrate can then be contacted with the liquid-phase precursor of the inorganic mineral, such as calcium phosphate, calcium carbonate, hydroxyapatite, strontium carbonate, calcium sulfate, calcium oxalate, calcium oxide, magnesium-bearing calcium carbonate or phosphate, or any polymorphs of these minerals.

[0046] The process of the subject invention can be carried out under a variety of conditions. For example, in the case of an aqueous system, the process can be carried out at a temperature of about 0° C to about 100° C. Preferably, the process is carried out at about 37° C, to match physiological conditions. The process can be carried out at a pH in the range of about 5 to about 10. Preferably, the process is carried out at a pH of about 7.0 to about 7.8 and 1 atm. More preferably, the process is carried out at a pH of about 7.4.

[0047] The type of reaction vessel or vessels utilized for preparing the composite of the subject invention, or their sizes, are not critical. Any vessel or substrate capable of holding or supporting the organic and inorganic phases so as to allow the reaction to take place can be used. Preferably, the supersaturation is gradually increased, allowing time for the acidic polymer to induce and stabilize the liquid-phase mineral precursor. It should be understood that, unless expressly indicated to the contrary, the terms "adding", "contacting", "mixing", "reacting", and grammatical variations thereof, are used interchangeable to refer to the mixture of reactants of the process of the present invention (*e.g.*, acidic polymer additives, calcium-containing solution, and so forth), and the reciprocal mixture of those reactants, one with the other (*i.e.*, vice-versa).

[0048] Where collagen is used as the organic phase of the composite of the subject invention, the collagen can be obtained from mineralized or unmineralized sources. Preferably,

the collagen is obtained from an unmineralized collagen source. Therefore, the collagen may come from biological sources such as bone, tendons, skin, or the like. Preferably, the collagen involves a combination of three strands of α_2 collagen chains. The collagen can be obtained from a young, intermediate, or mature animal, such as mammals or avians. Examples of convenient animal sources of collagen include chicken, turkey, bovine, porcine, or equine sources. The collagen can also be recombinant collagen, or artificially synthesized. Collagen of various types can be used as any of collagen types I-XX, or combinations thereof.

[0049] Fluid-swellable materials (and particularly waterswellable materials) other than collagen can also be utilized as organic substrates within the composites of the subject invention. For example, sponges composed of bioresorbable polymers (such as hyaluronic acid, polyglycolic acid (PLGA), or poly(L-lactic acid) (PLLA)) can serve as the organic substrate, instead of collagen, or in addition to collagen. Other examples of fluid-swellable materials appropriate as organic substrates include elastin, polyanhydrides, polyorthoesters, chitin, chitosan, polyphosphazenes, polylactides, glycosaminoglycans (including dermatan sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, and heparin). Any fluid-swellable material can be utilized as the organic substrate, provided that the material can swell sufficiently to absorb the liquid-phase mineral precursor. Preferably, the fluid-swellable material is bioresorbable and/or biocompatible so that cells can infiltrate and grow within the composite and eventually remodel it into natural bone tissue. However, bioresorbability may not be necessary if the composite material is biocompatible and has sufficient mechanical properties for long-term or permanent application. Other suitable fluid-swellable polymers include poly(lactic-co-glycolic acid) (PLGA), gelatin, polyacrylates, polyesters, polyethers, and crosslinked versions of all these polymers, wherein the crosslinking is accomplished via reactive endgroups (epoxy, acrylate, etc.), radiation, etc.

[0050] The fluid-swellable matrix can be surface modified before, during, or after mineralization using any of a variety of means known in the art, such as plasma treatment, etching, ion implantation, radiation, electron beam, chemical functionalization, grafting, photopolymerization, adsorption, or combinations thereof.

[0051] One or more of a variety of acidic polymers, such as acidic short-chained polymers, can be utilized to initiate the amorphous liquid-phase mineral precursor, including different polymers and biological materials. Polyacrylic acid (PAA), polymethacrylates (PMA),

sulfonated polymers, phosphorylated proteins, peptides and polymers, sulfated glycoproteins, polyaspartic acid, polyglutamic acid, polyaspartate, polyvinyl phosphate, and blends or copolymers of these materials, individually and in mixtures, can be utilized to induce the liquid-phase separation, for example. A range of polymer molecular weights can be suitable if the other variables of the crystallizing conditions are appropriately modified to generate the PILP phase. Preferably, molecular weights in the range of 2,000 to 15,000g/mol enhance the ability to induce formation of the precursor.

[0052] The desired hardness of the composite of the subject invention can be achieved by varying the weight ratio of the organic phase (such as collagen) and the inorganic phase (such as calcium phosphate and/or calcium carbonate), and the physical nature of the phases (such as degree of crystallinity, density, fibrillar structure of matrix, *etc.*).

[0053] The composite of the subject invention can be applied as a film or coating on a substrate. The substrate can be composed of any material, such as metal, polymer, and/or ceramic materials (such as hip joints, knee joints, dental implants, spinal fusion cages, and bone fillers). The composite can also be formed by sequential formation of layers, in which the orientation of the polymer in adjacent layers may or may not be controlled, similar to a laminated composite.

[0054] The present invention further concerns a method of treating a patient having a bone defect by applying a composite described herein to the site of the bone defect. As used herein, the term "patient" refers to any human or non-human animal suffering from a bone defect. According to the method of the subject invention, a therapeutically effective amount of the composite can be applied at the site of a bone defect to partially or fully restore structural integrity to the bone. Once applied, the composite of the subject invention can function as a filler (or partial filler) or plug, to mend the bone defect. The amount to be applied will depend upon the size and nature of the bone defect, and the clinical outcome that is sought. The composite can be applied in a malleable form, for example, as a paste or putty, such that the administered composite takes the shape of the bone defect. Alternatively, the composite can be molded pre-cast into a desired shape (such as the shape of the defect) using polymer composite molding methods known to those of ordinary skill in the art, and the molded composite can be administered as a solid or semi-solid article. Thus, the size, volume, thickness, and shape of the molded article can be controlled, as desired. The composite can be applied in particulate form.

According to the method of the subject invention, the composite can be applied so that it directly contacts existing bone adjacent to, or defining, the bone defect site, or the composite can be contacting another implant, or both.

[0055] The composite of the subject invention can be applied to the bone defect site as a liquid. Once applied, with a syringe for example, the liquid composite can coagulate or cure ("set") shortly after application to form a solid.

[0056] The composite of the subject invention can be used as a vehicle for the *in situ* delivery of biologically active agents. The biologically active agents incorporated into, or included as an additive within, the composite of the subject invention can include, without limitation, medicaments, growth factors, vitamins, mineral supplements, substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness, substances which affect the structure or function of the body, or drugs. The biologically active agents can be used, for example, to facilitate implantation of the composite into a patient and to promote subsequent integration and healing processes. The active agents include, but are not limited to, antifungal agents, antibacterial agents, anti-viral agents, anti-parasitic agents, growth factors, angiogenic factors, anaesthetics, mucopolysaccharides, metals, cells, and other wound healing agents. Because the processing conditions can be relatively benign (physiological temperature and pH), live cells can be incorporated into the composite during its formation, or subsequently allowed to infiltrate the composite through tissue engineering techniques.

[0057] As indicated above, cells can be seeded onto and/or within the organic/inorganic composites of the present invention. Likewise, tissues such as cartilage can be associated with the composites prior to implantation within a patient. Examples of such cells include, but are not limited to, bone cells (such as osteoclasts, osteoblasts, and osteocytes), blood cells, epithelial cells, neural cells (*e.g.*, neurons, astrocytes, and oligodendrocytes), and dental cells (odontoblasts and ameloblasts). Seeded cells can be autogenic, allogenic, or xenogenic. Seeded cells can be encapsulated or non-encapsulated.

[0058] Examples of antimicrobial agents that can be used in the present invention include, but are not limited to, isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, cikprofloxacin, doxycycline, ampicillin, amphotericine B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine,

atovaquone, paromomycin, diclarazaryl, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, and silver salts, such as chloride, bromide, iodide, and periodate.

[0059] Growth factors that can be incorporated into the composite of the present invention include, but are not limited to, bone growth factors (e.g., BMP, OP-1) basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), nerve growth factor (NGF), epidermal growth factor (EGF), insulin-like growth factors 1 and 2 (IGF-1 and IGF-2), platelet-derived growth factor (PDGF), tumor angiogenesis factor (TAF), vascular endothelial growth factor (VEGF), corticotropin releasing factor (CRF), transforming growth factors alpha and beta (TGF- α and TGF- β), interleukin-8 (IL-8), granulocyte-macrophage colony stimulating factor (GM-CSF), the interleukins, and the interferons.

[0060] Other agents that can be incorporated into the composite of the subject invention include acid mucopolysaccharides including, but not limited to, heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose, agarose, chitin, dextran, carrageenin, linoleic acid, and allantoin.

[0061] Proteins that can be incorporated into, or included as an additive within, the composite of the subject invention include, but are not limited to, collagen (including cross-linked collagen), fibronectin, laminin, elastin (including cross-linked elastin), osteopontin, osteonectin, bone sialoproteins (Bsp), alpha-2HS-glycoproteins, bone Gla-protein (Bgp), matrix Gla-protein, bone phosphoglycoprotein, bone phosphoprotein, bone proteoglycan, protolipids, bone morphogenetic protein, cartilage induction factor, platelet derived growth factor and skeletal growth factor, enzymes, or combinations and biologically active fragments thereof. Other proteins associated with other parts of human or other mammalian anatomy can be incorporated or included as an additive, include proteins associated with cartilage, such as chondrocalcining protein, proteins associated with dentin, such as phosphoryin, glycoproteins and other Gla proteins, or proteins associated with enamel, such as amelogenin and enamelin. Agents incorporated into the composite of the subject invention may or may not facilitate or enhance osteoinduction. Adjuvants that diminish an immune response can also be used in conjunction with the composite of the subject invention.

[0062] The biologically active agents can first be encapsulated into microcapsules, microspheres, microparticles, microfibers, reinforcing fibers and the like to facilitate mixing and

achieving controlled, extended, delayed and/or sustained release. Encapsulating the biologically active agent can also protect the agent against degradation during formation of the composite of the invention.

[0063] Additionally, the biologically active agents can be pendants attached to the organic or inorganic phase. The attachment can be facilitated through covalently linking the agent to the organic or inorganic phase, or through the use of hydrogen bonding.

[0064] In a preferred embodiment of the invention, the biologically active agent is controllably released into a mammal when the composite of the invention is implanted into a mammal, due to bioresorption relying on the time scale resulting from cellular remodeling. Preferably, the composite of the subject invention is used to replace an area of discontinuity in the bone tissue in the mammalian body. The area of discontinuity in the bone can be as a result of trauma, disease, genetic defect, tumor, or surgery, for example.

[0065] The composite of the subject invention can be formulated into a variety of shapes suitable for its function as a bone graft substitute, such as a plate, pin, rod, screw, anchor, tack, arrow, staple, button, or other regular or irregular shape. The composite of the present invention can be formulated as a three-dimensional scaffold and, optionally, seeded with one or more cell types for implantation within a patient. For example, a highly mineralized, collagen/hydroxyapatite composite with a nanostructured architecture similar to parallel-fibered compact bone can be fabricated using the PILP process of the present invention. Using the method of the present invention, mineralized scaffolds with the composition and mechanical properties of bone can be produced. These scaffolds can exhibit osteoconductive properties that promote rapid infiltration of cells into the implant material for neovascularization and osseous ingrowth. Hence, the organic/inorganic composites produced by the methods of the present invention can be sufficiently osteoconductive, load-bearing, and bioresorbable so as to replace the current “gold standard”, which requires harvesting of autogenous bone tissue.

[0066] The term “intrafibrillar”, as used herein, is used to specify the location of the crystallites, which has been described as a “deck-of-cards” arrangement of iso-oriented nanocrystals that are embedded within any interstitial spaces within the organic matrix. In the case of collagen, these spaces include the gaps and grooves of the assembled collagen fibrils (Traub, W. *et al.* [1992] *Matrix*, 12:251-255; Weiner, S. *et al.* [1991] “Organization of Crystals in Bone”, in Mechanisms and Phylogeny of Mineralization in Biological Systems, Suga, S. and

Nakahara, H. (eds.), pp. 247-253; Traub, W. *et al.*, [1989] *Proc. Natl. Acad. Sci.*, 86:9822-9826, Springer-Verlag Publishers, New York, N.Y.). Thus, as used herein, intrafibrillar means that the amorphous precursor penetrates the fluid-swellable matrix of the organic substrate, and mineral crystals grow on and within the matrix structure, and on and within any underlying substructure, such as fibers, meshes, polymer strands, etc. For example, in the case of fibrous organic substrates, the amorphous mineral phase penetrates the fibers (and fibrils, if present) of the fibrous substrate, and mineral crystals grow on and within the fibers (and fibrils, if present) of the organic substrate. As used herein, the term "interfibrillar" means that the mineral crystals grow within the fluid-swellable matrix, but do not necessarily penetrate the interior of the fibrillar substructure generated from the self-assembly of the tropocollagen molecules.

[0067] The term "bone defect", as used herein refers to any bone deficient region, such as a void, gap, recess, or other discontinuity in the bone. The bone defect can be artificially or naturally established, and can occur due to disease or trauma, for example. Thus, the bone defect can occur as a consequence of pathologic, inflammatory, or tumor diseases, surgical interventions, congenital defects, or bone fractures, and the like. For example, in the case of certain diseases, such as bone tumors, the bone defect is artificially established by removing the tumor tissue. Thus, according to the method of the subject invention, the composite can be applied, for example, to repair periodontal defects, for craniofacial reconstruction, joint reconstruction, fracture repair, to conduct orthopedic surgical procedures, and spinal fusion, for example. The term "bony defect" is also intended to include anatomical sites where augmentation to a bony feature is desired by the patient in the absence of disease or trauma, such as in elective cosmetic surgery. Thus, the "defect" can be one that is subjectively perceived by the patient, and where augmentation of the bone deficient region is desired.

[0068] The term "biocompatible", as used herein, means that the material does not elicit a substantial detrimental response in the host. It should be appreciated that when a foreign object is introduced into a living body, that the object may induce an immune reaction, such as an inflammatory response that will have negative effects on the host. As used herein, the term "biocompatible" is intended to include those materials that cause some inflammation and/or tissue necrosis, provided that these effects do not rise to the level of pathogenesis. Various assays known in the art can be utilized to assess biocompatibility. For example, the following assays can be conducted to determine biocompatibility of cells to the composites: alkaline

phosphatase activity (e.g., using Diagnostic kit 245, SIGMA) for a particular cell phenotype (e.g., osteoblast), methylthiazol tetrazolium (MTT) proliferation assay (Zund G. et al. [1999] *European Journal Cardiothoracic Surgery* 15:519-524; Deng Y. et al. [2002] *Biomaterials* 23:4049-4056), histology/histomorphometry, and SEM analysis. Response variables for subsequent statistical analysis would include, for example, cell count, alkaline phosphatase expression, cell distribution, and cell/tissue penetration.

[0069] The term "biodegradable", as used herein, means capable of being biologically decomposed. A biodegradable material differs from a non-biodegradable material in that a biodegradable material can be biologically decomposed into units which may be either removed from the biological system and/or chemically incorporated into the biological system.

[0070] The term "bioresorbable", as used herein, refers to the ability of a material to be resorbed *in vivo*. "Full" resorption means that no significant extracellular fragments remain. The resorption process involves elimination of the original implant materials through the action of body fluids, enzymes, or cells. Resorbed calcium carbonate may, for example, be redeposited as bone mineral, or by being otherwise re-utilized within the body, or excreted. "Strongly bioresorbable", as the term is used herein, means that at least 80% of the total mass of material implanted is resorbed within one year.


[0071] The term "polymorph", as used herein, refers to inorganic minerals that are identical chemical compositions but different crystal structures.

[0072] The terms "comprising", "consisting of", and "consisting essentially of" are defined according to their standard meaning and may be substituted for one another throughout the instant application in order to attach the specific meaning associated with each term.

Materials and Methods

[0073] Polymer-Induced Liquid-Precursor (PILP) Process. The preparation of a PILP phase has been described previously (Gower, L.B. and D.J. Odom *J. Crystal Growth* 2000, 210(4):719-734; Gower, L.A. [1997] "The Influence of Polyaspartate Additive on the Growth and Morphology of Calcium Carbonate Crystals," Doctoral Thesis, Department of Polymer Science and Engineering, University of Massachusetts at Amherst, 1-119; Gower, L.A. and D.A. Tirrell *J. Crystal Growth* 1998, 191(1-2):153-160). The general process introduces the acidic polymer into an aqueous salt solution which is slowly raised in supersaturation. One common

method for raising supersaturation is to slowly introduce one of the ionic species, for example using a modified vapor diffusion technique developed by Addadi *et al.* (Addadi, L. *et al.* [1985] *Proc. Natl. Acad. Sci. USA*, 82:4110-4114), in which ammonium carbonate $(\text{NH}_4)_2\text{CO}_3$ vapor, produced by decomposition of its powder, diffuses into a solution containing calcium chloride CaCl_2 and the acidic polymeric additive. This multistage process is illustrated by the formula:



[0074] Alternatively, calcium phosphate (CaP) readily forms an amorphous gel prior to crystallization, which is unlike the PILP phase (a truly liquid-like material and has a distinct phase boundary that can be acted upon by capillary forces). In the case of bone formation, neither an amorphous solid or gel would be sufficiently fluidic to be drawn into the nanoscopic spaces of collagen, which is presumed necessary for leaving the matrix embedded with mineral precursor and ultimately nanocrystallites. However, as seen in the SEM and TEM images in Figures 2A and 2B, CaP "droplets" were generated using a combination of polyanionic additives (polyaspartate and polyvinyl phosphonate) as shown in the equation below.



[0075] Energy dispersive spectroscopy (EDS) (Figure 2C) and x-ray diffraction (XRD) were used to confirm composition and phase of the mineral, which was hydroxyapatite.

[0076] Typically, the crystal products are deposited onto a thin glass coverslip (22 mm D.) that is placed in the crystallizing solution, which can then be examined by polarized light microscopy (including *in situ* examination with ultra-long-working-distance objectives), or gold coated for scanning electron microscopy (SEM). The exact concentration of the reactants depends on the experiment, and is provided below.

[0077] Formation of Fibrous Crystals. The formation of fibrous calcium carbonate was accomplished by using the PILP process to deposit CaCO_3 on glass cover slips. The cover slips were cleaned by soaking overnight in a bath of 12N H_2SO_4 /Nochromix solution, followed by a distilled water rinse, and a final rinse with ethanol. Each of the cover slips was placed in a

Falcon polystyrene petri dish (3.5 cm D.), to which was added 2.7 mL of a filtered 9 mM CaCl₂ solution (CaCl₂·2H₂O, 98+% pure, SIGMA). Poly(aspartic acid) was added to a final concentration of 28 µg/ml (poly-L-aspartic acid-sodium salt, M_w (vis) = 35600, SIGMA), and distilled water was added to the petri dishes using a micropipette to bring the final volume to 3 mL. A control dish, containing no polymeric additives, was run in parallel with each of the experiments. All solutions were prepared with doubly distilled water and filtered using 0.2 µm GELMAN ACRODISC syringe filters. The dishes were covered with stretched parafilm, into which three holes were punched, and placed in a 10 dessicator. Vapor diffusion of ammonium carbonate was accomplished by adding three small vials (5 mL) of crushed ammonium carbonate (that had been covered with stretched parafilm and punched with one hole) in the dessicator with the calcium/polymer solutions. The dessicators were then held at room temperature (25° C) for one week, at which time the glass slides were removed from the solution, rinsed in a small beaker of water and then ethanol. The glass slides were then examined using an Olympus BX-60 optical microscope in transmission mode, using crossed polars and an optional first-order-red wave plate.

[0078] Mineralization of Collagen. Three different collagen substrates were mineralized with CaCO₃: bovine collagen (type-I, insoluble from bovine Achilles tendon (ALDRICH), CELLAGEN sponge (ICN), which is also type-I collagen that is fabricated into 1mm thick porous sponges, and AVITENE Ultrafoam hemostatic sponge, which is a type-I collagen sponge with 2-100 µm pores. Either 2-3 strands of fibrous bovine collagen, or 1/8" x 1/16" strips of CELLAGEN sponge, were placed in the crystallizing dishes and the crystallization process was performed as described above. The bovine collagen was mineralized using a solution of 12 mM CaCl₂ and 200 µg/ml polyaspartic acid (poly-L-aspartic acid-sodium salt, M_w (vis) = 8600; SIGMA), followed by vapor diffusion of the carbonate. The CELLAGEN sponge was mineralized using 12 mM CaCl₂ and 200 µg/ml polyacrylic acid (polyacrylic acid-sodium salt, M_w (vis) = 5100; SIGMA). The mineralized collagen was removed from the solution, rinsed in a small beaker of water and then ethanol. The collagen samples were then examined using an OLYMPUS BX-60 optical microscope (in transmission mode, using crossed polars and an optional first-order-red wave plate) and subsequently Au/Pd coated and examined with a JEOL 6400 SEM instrument. The AVITENE Ultrafoam collagen was mineralized using the same procedure for mineralizing the CELLAGEN sponges by adding micromolar amounts ranging

from 10-200 μm of polyaspartic acid (PAA, MW 5100, ALDRICH) and a calcium chloride solution. The mineralized AVITENE Ultrafoam collagen was crushed using a liquid N₂ mortar and pestal and put into solution. The solution was sampled and specimens placed on a copper TEM grid.

[0079] Acid Etch and Bleach Treatment. In order to determine the structure of the calcium carbonate deposited on the collagen fibers, and the extent of the mineral penetration (acid and bleach respectively), the mineralized composites were exposed to either a 0.1 N HCl solution (to etch mineral) or a 10% bleach solution (to degrade collagen) for 15 minutes at 23° C. After treatment, the samples were thoroughly rinsed in de-ionized water in order to avoid any contamination by the remaining acid or bleach.

[0080] Scanning Electron Micrograph (SEM) Analysis. The samples (untreated, acid etched and bleached) were dried under vacuum at 30-40° C overnight and subsequently Au/Pd coated and examined with a JEOL 6400 SEM instrument. In addition to the mineralized samples, a control sample of as received CELLAGEN sponge was also coated and examined.

[0081] XRD Analysis. Three different samples, approximately 1x1 cm² were prepared for x-ray analysis. The first sample was as received, non-mineralized CELLAGEN, the second sample was mineralized without the presence of polymeric additive, and the third sample was mineralized for 7 days at 4° C in the presence of μM quantities of PAA. The samples were run on a PHILIPS XRD 2500 at 40 KV and 20 mA. Since the crystal composite was not expected to vary between the 5 different samples mineralized in the presence of polymeric additive, the sample mineralized for 1 cycle was chosen for XRD analysis.

[0082] TEM Analysis. The AVITENE Ultrafoam hemostatic collagen samples were examined using a transmission electron microscope (TEM) in Brightfield (BF) and diffraction modes.

Example 1—Mineral Fibers

[0083] In the absence of acidic polymeric additives, rhombohedral crystals of calcite approximately 40 μm in size were produced. In the presence of poly(aspartic acid), nonequilibrium morphologies were produced, such as crystalline thin films of calcite and aggregates of distorted crystals (which seem to be a hybrid of solution and PILP formed crystals and are a common by-product of the *in vitro* reaction). Interestingly, some of the aggregates

contained fibrous crystalline extensions, as shown in Figures 3A and 3B. In one study, in which time-lapse video was used to envisage their formation, it was observed that these fibers are initially isotropic, and they “grow” from isotropic gelatinous globules. The “fibers” became birefringent with time (several hours), and appear to be single-crystalline, as evidenced by the uniform extinction direction in cross-polarized light, as shown in Figures 3A and 3B. It became apparent that these amorphous fibers were being “extruded” from the central globule because, in the one case that was monitored *in situ*, the isotropic fiber had a large knob at the tip, which slowly moved further and further away from the central aggregate. In other words, crystal growth did not occur at the tip of the fiber, but rather the fiber was slowly emerging from the central globule.

[0084] A possible explanation for this phenomenon could be that the central globule formed an outer crust, which occasionally would burst due to build up of osmotic pressure, releasing the PILP precursor contents within (this explanation is based on a similar phenomenon that occurs in “silicate gardens” (Jones, D.E.H. and U. Walter *J. Colloid Interface Sci.* 1998, 203:286-293). Interestingly, the released contents apparently maintain the relatively uniform cross-sectional diameter, as would be expected of an extruded fiber. This demonstrates the significance of the phase boundaries of this precursor phase, because if the contents released were simply an ionic solution, one would expect it to just disperse into the surrounding solution.

[0085] Energy dispersive spectroscopy (EDS) shows that these fibers are indeed calcium carbonate (as expected since very little polymer is added to these reactions), but the crystal polymorph, fluidity of the precursor phase, and details of this process remain to be determined. Nevertheless, the general concept has been demonstrated- mineral fibers can be “extruded” at room temperature via a liquid-phase mineral precursor.

[0086] Wang *et al.* (Wang, R.Z. *et al.* [1997] *Phil. Trans. R. Soc. Lond. B*, 352:469-480) suggest that there is an organic sheath covering the fibers in the sea urchin teeth. If this is the case, then an amorphous liquid-phase precursor that either fills this organic sheath, or uses the sheath as a guide during extrusion, is an attractive hypothesis to explain these unusual fibrous morphologies. Likewise, the assembly of amelogenins and other macromolecules in vertebrate enamel formation could help direct an extrusion process (so that a random assortment of fibers does not result, as in our simple experiment). Clearly, the microstructure of the rods in the two different mineral systems is different (single-crystalline calcite vs. polycrystalline HAP), but the

concept of fiber formation is a key point, which may be relevant to both the vertebrates and invertebrates.

Example 2--Mineralization of Collagen with Calcium Carbonate

[0087] The PILP mineralization of bovine Achilles tendon type-I collagen showed interesting results. The individual fibers of the bovine collagen became coated or encrusted by a film of CaCO_3 . In some regions on the collagen fibers, the mineral film was patchy and in the form of isolated tablets (Figures 4A and 4B). Because there is a lack of facets in PILP formed crystals, energy dispersive spectroscopy was used to verify that these films and tablets are composed of CaCO_3 . Interestingly, the CaCO_3 "tablets" appear to have preferentially deposited along the fibers in a banded pattern (Figures 4A & 4B). It is not clear if the PILP phase was deposited in those locations due to topography (such as defects or kinks along the crimped collagen backbone), or if some more specific templating interaction is occurring between the PILP phase and organic matrix.

[0088] The CELLAGEN sponge (which is reconstituted bovine collagen) provides a better substrate onto which to deposit PILP phase because it has a flat and compact surface, as seen in the SEM photomicrograph of untreated CELLAGEN in Figure 5A. Upon mineralization of the sponge without polymeric addition (Figure 5B), large calcite crystals ($\sim 20\text{-}40\mu\text{m}$) grew on the surface of the sponge. Evidently collagen is a reasonably good substrate for heterogeneous nucleation of calcite. When the sponge was mineralized using the PILP process, by adding polymeric additive (polyacrylic acid in this case), the mineral phase deposited as a thick patchy film on the surface of the sponge (Figure 5C). A higher magnification view of one of these patches shows that the individual collagen sub-fibers are coated or encased by the mineral (Figure 5D), which is why the mineral coating appears to be so thick since it is actually a composite structure. It was noted that this mineral coating serves as a protective layer against beam damage during SEM observation. For example, Figure 5D shows a crack that formed during SEM analysis on the non-mineralized region of the sponge (bottom half of the figure), which was halted by the mineralized portion (upper half of the figure). In addition, the mineral encased fibers exhibit charging without degradation, unlike the unprotected fibers.

[0089] In Figures 6A and 6B, a periodic banding pattern can be seen on the mineral coatings of these fibers. In the mineralized bovine collagen shown in Figure 6A, blebbing is

apparent along the length of encapsulating mineral towards the end of the fiber. Unlike the banding pattern in Figures 4A and 4B, the spacing of the banding pattern here is submicron. At the top region of the photo, it can be seen that this fiber did not fully mineralize. The individual sub-fibers of the collagen became separated as they densified during sample dehydration (in preparation for SEM analysis) because the ends were restrained by the surrounding mineralized tissue. This would suggest that some amount of mineral is intercalating into the large fiber bundles and coating the individual sub-fibers.

[0090] In Figure 6B, which is mineralized CELLAGEN sponge, the blebbing is so pronounced that disc-shaped entities appear along the whole length of the fibers. The relative periodicity of the blebbing (~380 μm) seems to suggest that it is somehow related to the periodicity of the swollen collagen fibers, yet the spacing between the bands is ~ 6 times the collagen hole-overlap periodicity (64 nm), but an order of magnitude less than the distance between the natural crimp in collagen (~ 1 μm - 10 μm). The periodicity is not a precise match with native collagen; however, it is likely that the reconstituted collagen does not assemble into as precise a periodic structure as natural collagen. It is interesting that the encasement with mineral seems to capture this periodic structure, suggesting that perhaps the mineral is preferentially located in the gap zones of the collagen, which upon dehydration of the sample for SEM analysis, leaves those regions thicker than the surrounding regions containing less mineral and more organic matrix (which dehydrate and densify to a larger extent). Notably, Bradt *et al.* (Bradt, J.H. *et al.* [1999] *Chem. Mater.* 11:2694-2701) have deposited HAP on collagen in the presence of poly(aspartic acid) and found TEM evidence that some plate-like crystals of HAP were associated with the gaps in the collagen fibrils. Their results are interesting but it is likely that a more potent acidic protein will be required to fully generate a liquid-phase precursor for the calcium phosphate system.

[0091] PILP mineralization of the AVITENE ultrafoam hemostatic sponge yielded similar results to CELLEGGEN sponge mineralization. Samples that were mineralized in the absence of polymeric additives showed simple calcite nucleation on the surface of the collagen (Figure 7B). Upon addition of micromolar amounts of (10-200 μm) polyaspartic acid (PAA; MW 5100, ALDRICH), each individual collagen fiber appeared to be mineralized (Figures 7C and 7D). As with the CELLAGEN, there were sections that were partially mineralized (Figure 7C) and those that were fully mineralized (Figure 7D).

Example 3—Mineralization of Collagen with Calcium Phosphate

[0092] The results for the CaP system were very similar to the CaCO₃ system, but with some differences in the mineral texture. The XRD spectrum of the mineralized collagen (not shown) shows peaks consistent with HA, although some peak shifts and differences in peak intensities are noted, which seem to suggest polymer-mineral interactions are prevalent (Sivakumar, M. *et al.* [2002] *Biomaterials*, 23(15):3175-3181). The mineralized CELLAGEN was also subjected to an acid etch treatment to remove excess mineral, and showed very similar results to the CaCO₃ composites. A periodic banding pattern is seen for the more protected mineral (Figures 8A and 8B), and crystals have a similar disk-like morphology. At this point, it is not clear if these are single crystals, or just thick clumps of remnant mineral phase. In some regions of the sample, the mineral remnants were less organized and the morphology was different, exhibiting a more platy shape (Figure 8C). Without being bound by theory, it is presumed that these banding patterns are due to exclusion of impurities and shrinkage of the precursor phase during dehydration/solidification/crystallization, because similar incremental growth bands in non-templated mineral depositions have been observed.

[0093] Using a cryogenic mortar and pestal, CELLAGEN sponges mineralized with CaP PILP phase were crushed into a fine powder using liquid nitrogen. The powder was then dispersed in ethanol and sonicated for 5 minutes. A small drop of the solution was then pipetted onto a copper TEM grid and stained using a 1% phosphotungstic acid in 0.1M PBS (ph 7.4). The grids were then examined using a transmission electron microscope (TEM). As observed in Figure 9A, the unmineralized CELLAGEN sample (which was also prepared in the same manner as noted above), characteristic 67-70 nm quarter-staggered banding patterns appear in the bright field image. Since collagen is a pseudo-liquid crystalline polymer, there have been reports in the literature in which collagen has displayed a distinct diffraction pattern. Yet, in close agreement with the XRD diffraction patterns of CELLAGEN, the diffraction pattern of CELLAGEN in Figure 9B shows a similar pattern to that of the transmitted beam. Unlike Figure 9A, where there are only banding patterns present, in the bright field image of mineralized CELLAGEN, Figure 9C, there are numerous black spots within the collagen. These black spots (1-5 nm) infer a higher electron adsorption, most often caused by crystalline materials. While there is a possibility of these spots being a deposition of phosphotungstic acid crystals, the larger (50 – 70

nm) round particles highlighted by arrows correlate well with SEM images of the CaP PILP phase (Figure 2B), and thus are not believed to be a resultant of the stain. More interesting, however, are the diffraction patterns of the mineralized CELLAGEN sponge (Figure 2D). Unlike the diffraction pattern of pure collagen (Figure 9B), the selected area diffraction (SAD) of the mineralized fiber (Figure 9C) shows distinct diffraction along the long axis of the fiber (indicated by arrow).

[0094] Based on these results, it has been observed that a combination of polymers with phosphate and carboxylate functionality elicits the PILP process in CaP. With the phosphate containing polymer alone, there is some evidence of PILP phase, but it appears to be less fluidic than when a combination of the two polymers is used. Therefore, polypeptides comprising controlled amounts of aspartic acid and serine residues (for subsequent phosphorylation) using a solid-phase peptide synthesizer (ABI-433A) can be utilized. Fortunately, relatively low molecular weight (M.W.) polymers seem to be the most effective at inducing the PILP process (*e.g.*, within the range of about 50 to about 75 residues), which makes this synthetic route amenable for preparing small amounts of the “mimetic proteins” of interest. The following series of polypeptides can be used for further studies, and based on the results of these studies, tailor-made polymers can be designed for further optimization: (i) homopolymer of polyserine, phosphorylated to different degrees (M.W. = 5000 Da); (ii) alternating copolymer of Asp and Ser residues (with varying degrees of phosphorylation) (M.W. = 5000 Da); (iii) alternating copolymer of Asp, Ala, PSer, for reduced polarity (M.W. = 5000 Da); and block copolymer of Asp and Ser residues (with varying degrees of phosphorylation) (M.W. = 5000 Da), block size of about 10 residues.

[0095] The polymers can then be examined under similar conditions that were used for the previous studies, with variable concentrations of the polymeric additive. Based on the findings of these studies, further optimization and trends can be determined using statistically designed experiments (with other factors to consider, such as: Ca concentration, rate of phosphate additions, polymer concentration and M.W., Mg-ion additive, carbonate additive, and temperature).

Example 4—Mineralization of Polymeric, Fluid-Swellable Materials

[0096] The experiments described above with respect to collagen were similarly carried out on SCOTCH BRITE sponges.

[0097] Figure 11 shows an SEM of a SCOTCH BRITE sponge that has not been introduced to mineralizing solutions. It has micropores on the order of 0.75 microns – 2.0 microns in diameter. Figure 13 shows an SEM of a SCOTCH BRITE sponge that has been mineralized using the process of the subject invention. The sponge has been coated with non-equilibrium morphology calcium carbonate, thus clogging some of the pores. Specifically, the sponge shown in Figure 13 was mineralized four times (three days for each mineralization interval at 12mM CaCl₂, 200 µg/mL PAA (5100 m.w.), vapor diffusion of ammonium carbonate). After each interval, the solution was refreshed. Although the calcium carbonate coating is not obvious in the SEM of Figure 13, energy dispersive spectroscopy (EDS) measurements have been performed which ensure that the sponge was mineralized with calcium carbonate. In addition, whereas the unmineralized sponge would be extensively damaged by the electron beam from the EDS measurements (as organic materials do not conduct electricity with great ease), the mineralized samples, as the one shown in Figure 13, resisted electron beam damage due to the inorganic coating.

Example 5—*In Vitro* Cellular Response To Mineralized CELLAGEN

[0098] Rat bone marrow stem cells were harvested and seeded into 168 cm² culture flasks in standard culture media (DMEM supplemented with 10% FBS, 1% Penicillin/Streptomycin and dextrose). Cells were cultured for 14 days and media was changed on every fourth day. On day 14, the cells were trypsinized, counted and seeded in four 168cm² tissue culture dishes at a density of 1E6 cells/cm². Stem cells in three culture dishes were supplemented with OS media (Standard media + 100nM Dexamethasone + 10nM b-Glycerophosphate + 0.05mM Ascorbic acid) for an eight-day period to initiate and accelerate stem cell differentiation into osteoblasts. The remaining stem cells were supplemented with standard culture media to serve as controls.

[0099] Following this eight-day supplementation period, the osteoblasts and stem cells were trypsinized and counted with a hemocytometer. Osteoblasts and undifferentiated stem cells were seeded into three wells each of a 24-well plate at a density of 1.6E4 cells/well. The cells

were allowed to attach to the base of each well for a 3.5-hour period at which time an alkaline phosphatase (ALP) assay was performed to evaluate the extent of differentiation to osteoblast-like cells elicited by the OS media. Scaffolds composed of unmineralized CELLAGEN (A, n=6), mineralized CELLAGEN without polymer (B, n=6), and mineralized CELLAGEN with polymer (C, n=6) were sterilized using 2.5 Gy gamma irradiation. Two scaffolds per matrix type were reserved for negative control (no cells) SEM analysis; the remaining 4 scaffolds per matrix type were seeded with cells. Osteoblasts were seeded at a density of 4E4 cells/scaffold and aliquoted onto each scaffold in a total of 80 ul. All scaffolds were placed in separate 2 cm² wells of a 24 well plate. Osteoblasts were allowed to adhere to the scaffolds for a period of 3.5 hours, at which time the cell-containing scaffolds were removed and placed into new 2 cm² wells. The number of cells remaining in the 2 cm² incubation wells after removal of the scaffolds were quantified using a crystal violet assay. The cell-containing scaffolds were then supplemented with standard media and kept in a 37°C incubator for a seven-day period. After 12 hours and 7 days, osteoblasts were fixed in Karnovsky's solution and prepared for SEM imaging.

[00100] MSCs differentiated into the osteoblast lineage when cultured with OS media as confirmed with the ALP assay. After scaffold exposure to 4E+04 cells/scaffold for 3.5 hours, 25% of the cells adhered to the unmineralized CELLAGEN scaffold whereas 50% of the cells adhered to the mineralized CELLAGEN scaffold with or without polymer (Figure 18).

[00101] Absorbance values were compared to a previously constructed standard curve for determination of cell number. Initial comparisons with the standard curve were used to indicate the number of cells in the base of each 2 cm² well, and represent the number that had not successfully adhered to the scaffolds. The difference between this number and 4E+04 is the total number of cells that had successfully adhered to each matrix. Since all scaffolds that received osteoblasts were seeded simultaneously, the numbers given above were assumed to be valid for all scaffolds even though only 2 per treatment underwent this preliminary crystal violet stain and cell number determination.

[00102] Qualitative SEM imaging indicated adherence of osteoblasts onto the mineralized matrices (Figure 19A). The presence of calcified matrix nodules (Figure 19B) suggests interaction of differentiated osteoblasts with the scaffold. Positive identification of osteoblast within the matrix will be confirmed in future studies by quantifiable methylthiazol tetrazolium (MTT) proliferation assays. Figure 18 summarizes results of cell adhesion to the

mineralized CELLAGEN scaffolds. The mineralized scaffold without polymer (containing blocky calcite crystals) showed similar cell adhesion.

Example 6—Organic/Inorganic Composites Having Nanostructured Architecture of Bone

[00103] Using a PILP phase, the process of the present invention provides a means for generating intrafibrillar mineralization of organic substrates, such as collagen, yielding composites that are similar in composition and architecture as bone. However, the hierarchical levels of structure found in bone, which result from cellular processes, are difficult to duplicate synthetically. Therefore, the present inventors have developed methods to impart some of the more significant features of those of natural bone, such as microporosity for cell infiltration, and laminated structures for enhanced mechanical properties, to the composites of the present invention.

[00104] Compact bone has numerous osteonal canals. These osteons are comprised of concentric lamella of mineralized collagen (Weiner S, Traub W, Wagner HD [1999] Lamellar bone: structure-function relations. Journal of Structural Biology 126:241-255). As previously indicated, the ability to create such a complex structure *in vitro* by artificial mineralization processes is not possible. However, the present invention can overcome this hurdle. Using the process of the invention, layers of mineralized collagen films can be individually mineralized via the PILP mechanism. These layers, whether composed of pre-oriented or isotropically arranged collagen fibers, can then be cut into desired dimensions and wrapped around a mandrel 10. As shown in Figures 19A-19E, the mandrel 10, which represents the space occupied by the canal in natural osteons, will be used as a mechanical support (or form) in which to wrap the mineralized (or pre-mineralized) films or sheets 20. The mandrel 10 can be composed of a bioresorbable material, in which case it can remain as part of the composite. Alternatively, the mandrel 20 can be composed of a non-resorbable material, in which case it can be removed before implantation into a patient.

[00105] Since the mineralized layers do not have any natural tacticity, a coating of bioresorbable adhesive 30 (*e.g.*, polylactic acid, polyglycolic acid) can be applied between each individual layer wrapping. Alternatively, a cementitious adhesive layer can be applied, either via the PILP process of the present invention, or other bone paste materials, mimicking that of the “cement line” in natural bone. Once each individual osteon 50 is fabricated, many osteons 50

can be adhered to one another, as shown in Figure 19E, to form a much larger composite resembling the hierarchical structure of osteonal bone.

[00106] The organic fluid-swellable matrix of the composites of the present invention can be made so as to be oriented to achieve, for example, a parallel orientation, using flow fields, electric fields, magnetic fields, or combinations thereof (Murthy N.S. [1984] *Biopolymers* 23:1261-1267; Oh Y.R. *et al.* [1992] *J. Chem. Eng. Jpn.* 25:243-250; Dickinson R.B. *et al.* [1994] *Ann. Biomed. Eng.* 22:342-356; Trangillo R.T. *et al.* [1996] *Biomaterials* 17:349-357; Guido S. *et al.* [1993] *J. Cell. Sci.* 105:317-331). During the process of the invention, such oriented substrates act as templates for deposition of the amorphous mineral precursor into the fluid-swellable matrix. Therefore, an oriented nanocrystalline hydroxyapatite phase can be achieved, for example. Such a composite would more closely mimic the structure of parallel-fibered bone, providing important advantages such as tailored mechanical properties and contact guidance of cells during healing.

[00107] In one embodiment, the mineralized collagen sheets 20 can be adhered to one another by bioresorbable adhesives, such as those previously described, with each mineralized collagen layer placed in alternating orientation, to for a cross-ply architecture, as shown in Figures 20A-C.

Example 7—Porous Organic/Inorganic Composites

[00108] The ends of long bones have a much different macro-structure than that of the central shaft area of long bones. Underlying the cortical bone is trabecular or cancellous bone, which has a porous structure (Weiner S *et al.* [1999] *Journal of Structural Biology*, 126:241-255).

[00109] This type of macro-structure can be achieved using the process of the subject invention, in combination with certain processing techniques known in the art that can be applied to the organic matrix before, during, or after mineralization. For example, using a freeze-dried or direct templating process, collagen scaffolds with desired porosity can be produced with a range of pore sizes. Pore sizes in the range of about 100 to 200 microns are commonly used to enhance cell infiltration (osteocomductive material), which provides accessibility to the cells for remodeling the synthetic substitute into natural bone. These collagen scaffolds can then be mineralized via the PILP mechanism of the present invention in order to create a hard porous composite. Porous scaffolds can also be produced using organic substrates other than collagen.

[00110] Due to the size of the pores, larger homogenous structures can be prepared, which will enhance the capillary action of the secondary liquid phase produced by the PILP mechanism, allowing the precursor phase to be drawn further into the interior of the composite, thus allowing for complete mineralization.

[00111] Porosity of the composite can also be introduced and/or controlled by a variety of techniques, including freeze drying techniques; incorporation of porogens (*e.g.*, salts or other solubilizing substances that are removed subsequent to matrix formation); phase segregation of matrix media comprised of multiple phases (*e.g.*, block copolymers or immiscible blends), *e.g.*, using phase segregating polymers; high temperature sintering; and supercritical processing (creation of matrix in a supercritical state, which generates pores as the supercritical conditions are removed, most commonly as reduction in pressure or temperature) (Nehrer, S., *et al.* [1999] *Biomaterials*, 19:2313-2328; Zhang, R. *et al.* [1999] *J. Biomed. Mater. Res.* 44:446-455).

[00112] As indicated above, in order to obtain large samples with controlled porosity, a freeze-drying technique can be used. The porosity is preferably a continuous network to provide an open path for cells to travel to the center of the implant during healing. In addition, the use of the freeze-drying technique will result in a dense collagen scaffold such that subsequent mineralization will lead primarily to intrafibrillar mineralization, without mineralization of interfibrillar voids that would generate brittle regions of pure mineral phase. The intrafibrillar mineralization should lead to a nanostructured composite with enhanced mechanical properties that better mimic the properties of natural bone.

[00113] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

[00114] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.

Claims

We claim:

1. An organic/inorganic composite comprising an organic fluid-swellable matrix and an inorganic mineral phase, wherein said inorganic mineral phase is deposited on and absorbed within said fluid-swellable matrix when said inorganic mineral phase is in the form of a liquid phase mineral precursor.
2. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix comprises fibers, and wherein said inorganic liquid-phase mineral precursor is absorbed within said fibers.
3. The organic/inorganic composite of claim 2, wherein said fibers are arranged in parallel.
4. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix comprises an interior with interstitial space, and wherein said inorganic mineral phase is absorbed into said interstitial space when said inorganic mineral phase is in the form of a liquid phase mineral precursor, which subsequently solidifies.
5. The organic/inorganic composite of claim 4, wherein said fluid-swellable matrix further comprises an exterior, and wherein said inorganic liquid-phase mineral precursor is absorbed into said interstitial space and is coated on said exterior said fluid-swellable matrix.
6. The organic/inorganic composite of claim 5, wherein said inorganic liquid-phase mineral precursor deposited on said fluid-swellable matrix has a non-faceted topography when said liquid-phase mineral precursor becomes solidified.
7. The organic/inorganic composite of claim 1, wherein said inorganic mineral phase has an amorphous morphology or crystalline morphology.

8. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix comprises at least one material selected from the group consisting of collagen, elastin, polyanhydride, polyacrylate, polylactic-co-glycolic acid (PLGA), polyester, polyether, polyorthoester, chitin, chitosan, polyphosphazene, polylactide, glycosaminoglycan, gelatin, biopolymer, and biocompatible and bioresorbable polymer sponge.

9. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix has been surfaced-modified.

10. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix has been surface modified using a method selected from the group consisting of plasma treatment, etching, ion implantation, radiation, electron beam, chemical functionalization, grafting, photopolymerization, and adsorption.

11. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix comprises collagen.

12. The organic/inorganic composite of claim 11, wherein said collagen is selected from the group consisting of collagen type 1, collagen type 2, collagen type 3, collagen type 4, collagen type 5, collagen type 6, collagen type 7, collagen type 8, collagen type 9, collagen type 10, collagen type 11, collagen type 12, collagen type 13, collagen type 14, collagen type 15, collagen type 16, collagen type 17, collagen type 18, collagen type 19, and collagen type 20, or combinations thereof.

13. The organic/inorganic composite of claim 11, wherein said collagen comprises fibers, wherein each of said fibers comprises abutting fibrils with gaps arranged between said abutting fibrils, and wherein said liquid-phase mineral precursor is absorbed into said gaps by capillarity.

14. The organic/inorganic composite of claim 11, wherein said collagen has been surface modified.

15. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix comprises a polymer, wherein said polymer comprises a plurality of polymer chains separated by interstitial spaces, and wherein said inorganic liquid-phase mineral precursor is absorbed into said interstitial spaces.

16. The organic/inorganic composite of claim 1, wherein said polymer chains are cross-linked, either before or after mineralization.

17. The organic/inorganic composite of claim 15, wherein said polymer is a copolymer.

18. The organic/inorganic composite of claim 8, wherein said biocompatible and bioresorbable polymer sponge is selected from the group consisting of hyaluronic acid, polyglycolic acid, and poly(L-lactic) acid.

19. The organic/inorganic composite of claim 8, wherein said glycosaminoglycan is selected from the group consisting of dermatan sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, and heparin.

20. The organic/inorganic composite of claim 1, wherein said inorganic mineral phase comprises at least one member selected from the group consisting of calcium phosphate, calcium carbonate, hydroxyapatite, strontium carbonate, calcium sulfate, calcium oxalate, magnesium-bearing calcium carbonate, and magnesium-bearing calcium phosphate.

21. The organic/inorganic composite of claim 1, wherein said inorganic mineral phase comprises at least one member selected from the group consisting of hydroxyapatite, octacalcium phosphate, tricalcium phosphate, carbonated hydroxyapatite, fluorinated hydroxyapatite, brushite, magnesium containing hydroxyapatite, dicalcium phosphate dihydrate, and amorphous calcium phosphate.

22. The organic/inorganic composite of claim 1, wherein said composite further comprises one or more biologically active agents.

23. The organic/inorganic composite of claim 22, wherein said one or more biologically active agents are selected from the group consisting of medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness; substances affecting the structure or function of the body; drugs; antimicrobial agents; antifungal agents; antibacterial agents; antiviral agents; antiparasitic agents; growth factors; angiogenic factors; anaesthetics; mucopolysaccharides; metals; cells; acid mucopolysaccharides; proteins; enzymes, peptides; and wound healing agents.

24. The organic/inorganic composite of claim 23, wherein said antimicrobial agents are selected from the group consisting of isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, doxycycline, ampicillan, amphotericine B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclarazaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, and silver salts.

25. The organic/inorganic composite of claim 23, wherein said growth factors are selected from the group consisting of basic bone growth factor, fibroblast growth factor, acidic fibroblast growth factor, nerve growth factor, epidermal growth factor, insulin-like growth factor 1, insulin-like growth factor 2, platelet-derived growth factor, tumor angiogenesis, vascular endothelial growth factors alpha, vascular endothelial growth factor beta, interleukin-8, granulocyte-macrophage colony stimulating factor, interleukin, and interferon.

26. The organic/inorganic composite of claim 23, wherein said acid mucopolysaccharides are selected from the group consisting of heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose agarose, chitin, dextran, carrageenin, linoleic acid, and allantoin.

27. The organic/inorganic composite of claim 23, wherein said proteins are selected from the group consisting of collagen, fibronectin, laminin, elastin, osteopontin, osteonectin, bone sialoprotein, alpha-2HS-glycoproteins, bone Gla-protein, matrix Gla-protein, bone phosphoglycoprotein, bone phosphoprotein, bone proteoglycan, protolipids, bone morphogenetic protein, cartilage induction factor, platelet derived growth factor, skeletal growth factor, proteins associated with cartilage, proteins associated with dentin, and proteins associated with enamel.

28. The organic/inorganic composite of claim 23, wherein said one or more biologically active agents are seeded on said composite or embedded within said composite.

29. The organic/inorganic composite of claim 23, wherein said one or more biologically active agents are pendantsly attached to said organic fluid-swellable matrix or said inorganic mineral phase.

30. The organic/inorganic composite of claim 23; wherein said one or more biologically active agents are embedded within said organic fluid-swellable matrix, or the inorganic mineral phase, or both.

31. The organic/inorganic composite of claim 1, wherein said inorganic mineral phase is about 35% to about 50% by volume of said composite.

32. The organic/inorganic composite of claim 1, wherein said inorganic mineral phase is about 40% to about 45% by volume of said composite.

33. The organic/inorganic composite of claim 1, wherein said inorganic mineral phase is about 43% by volume of said composite.

34. The organic/inorganic composite of claim 1, wherein said organic fluid-swellable matrix is about 30% to about 40% by volume of said composite.

35. The organic/inorganic composite of claim 1, wherein said composite further comprises water, wherein said water is at about 20% to about 30% by volume of said composite.

36. The organic/inorganic composite of claim 1, wherein said organic/inorganic composite is in a form selected from the group consisting of an injectable liquid, a malleable paste, a malleable putty, a particulate, a film, a molded solid, and a preformed solid.

37. The organic/inorganic composite of claim 4, wherein said liquid phase precursor crystallizes in said interstitial space in said fluid-swellable matrix.

38. The organic/inorganic composite of claim 11, wherein said collagen comprises a plurality of parallel fibers, wherein said inorganic mineral phase is absorbed into said plurality of parallel fibers, and wherein crystals of said inorganic mineral phase are embedded within the organic matrix.

39. The organic/inorganic composite of claim 38, wherein said crystals are arranged parallel to the longitudinal axis of said plurality of parallel fibers.

40. The organic/inorganic composite of claim 1, wherein said organic/inorganic composite is porous.

41. The organic/inorganic composite of claim 40, wherein said pores range from about 50 microns to about 500 microns or more in diameter.

42. The organic/inorganic composite of claim 1, wherein said organic fluid-swellable matrix is porous.

43. The organic/inorganic composite of claim 40, wherein the microporosity is generated using freeze-drying techniques, supercritical processing, porogens, soluble salts or molecular compounds, phase segregating polymers, or high temperature sintering.

44. The organic/inorganic composite of claim 1, wherein said organic substrate is biocompatible and bioresorbable.

45. The organic/inorganic composite of claim 1, wherein said fluid-swellable matrix comprises a scaffold seeded with cells.

46. The organic/inorganic composite of claim 45, wherein cells are selected from the group consisting of bone marrow stem cells, osteoblasts, osteoclasts, osteocytes, blood cells, epithelial cells, odontoblasts, ameloblasts, cementoblasts, and neural cells.

47. The organic/inorganic composite of claim 1, wherein said organic fluid-swellable matrix comprises a film.

48. The organic/inorganic composite of claim 1, wherein said composite comprises a plurality of said organic substrates arranged as lamellae.

49. The organic/inorganic composite of claim 48, wherein said lamellae are arranged concentrically around a central void, in an osteon-like structure.

50. The organic/inorganic composite of claim 1, wherein said composite comprises a plurality of said organic fluid-swellable matrices, and wherein said composite further comprises an adhesive layer between each of said organic fluid-swellable matrices.

51. The organic/inorganic composite of claim 50, wherein said plurality of organic substrates have a parallel orientation.

52. The organic/inorganic composite of claim 50, wherein said plurality of organic substrates are arranged in an alternating orientation.

53. A process for making organic/inorganic composites, said method comprising contacting an acidic polymer with a mineralizing solution under conditions suitable to form an

inorganic liquid-phase mineral precursor, and contacting said inorganic liquid-phase mineral precursor with an organic fluid-swellable matrix, wherein said inorganic liquid-phase mineral precursor is absorbed into, and subsequently hardens within, said fluid-swellable matrix.

54. The process according to claim 53, wherein said acidic polymer has a molecular weight in the range of about 1000 to about 100,000 g/mol.

55. The process according to claim 53, wherein said second contacting step is repeated until said organic fluid-swellable matrix is sufficiently mineralized.

56. The process according to claim 53, wherein said acidic polymer comprises at least one member selected from the group consisting of polyacrylic acid, polymethacrylic acid, sulfonated polymers, phosphorylated proteins or peptides, phosphorylated polymers, sulfated polysaccharides, sulfated glycoproteins, polyaspartic acid, polyglutamic acid, polyaspartate, polyvinyl phosphate, and polyvinyl phosphonate, or combinations thereof.

57. The process according to claim 53, wherein said fluid-swelling matrix comprises a material selected from at least one member of the group consisting of collagen, elastin, polyanhydride, polyorthoester, chitin, chitosan, polyphosphazene, polyactide, glycosaminoglycan, gelatin, and biocompatible and bioresorbable polymer sponge.

58. The process according to claim 53, wherein said fluid-swelling matrix comprises collagen.

59. The process according to claim 53, wherein said collagen is selected from the group consisting of collagen type 1, collagen type 2, collagen type 3, collagen type 4, collagen type 5, collagen type 6, collagen type 7, collagen type 8, collagen type 9, collagen type 10, collagen type 11, collagen type 12, collagen type 13, collagen type 14, collagen type 15, collagen type 16, collagen type 17, collagen type 18, collagen type 19, and collagen type 20, or combinations thereof.

60. The process according to claim 57, wherein said biocompatible and bioresorbable polymer sponge is selected from the group consisting of hyaluronic acid, polyglycolic acid and poly(L-lactic) acid.

61. The process according to claim 57, wherein said glycosaminoglycan is selected from the group consisting of dermatan sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate and heparin.

62. The process according to claim 53, wherein said inorganic liquid-phase mineral precursor comprises at least one member selected from the group consisting of calcium phosphate, calcium carbonate, hydroxyapatite, strontium carbonate, and calcium sulfate, calcium oxalate, magnesium-bearing calcium carbonate, and magnesium-bearing calcium phosphate.

63. The organic/inorganic composite of claim 1, wherein said inorganic mineral phase comprises at least one member selected from the group consisting of hydroxyapatite, octacalcium phosphate, tricalcium phosphate, carbonated hydroxyapatite, fluorinated hydroxyapatite, brushite, magnesium containing hydroxyapatite, dicalcium phosphate dihydrate, and amorphous calcium phosphate.

64. The process according to claim 53, wherein said method further comprises associating a biologically active agent within said composite.

65. The process according to claim 64, wherein said biologically active agents comprise at least one member selected from the group consisting of medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness; substances affecting the structure or function of the body; drugs; antimicrobial agents; antifungal agents; antibacterial agents; antiviral agents; antiparasitic agents; growth factors; angiogenic factors; anaesthetics; mucopolysaccharides; metals; cells; acid mucopolysaccharides; proteins; enzymes, peptides; and wound healing agents.

66. The process according to claim 65, wherein said antimicrobial agents are selected from the group consisting of isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, doxycycline, ampicillan, amphotericine B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclarazaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, and silver salts.

67. The process according to claim 65, wherein said growth factors are selected from the group consisting of basic fibroblast growth factor, bone growth factor, acidic fibroblast growth factor, nerve growth factor, epidermal growth factor, insulin-like growth factor 1, insulin-like growth factor 2, platelet-derived growth factor, tumor angiogenesis, vascular endothelial growth factors alpha, vascular endothelial growth factor beta, interleukin-8, granulocyte-macrophage colony stimulating factor, interleukin, and interferon.

68. The process according to claim 65, wherein said acid mucopolysaccharides are selected from the group consisting of heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose agarose, chitin, dextran, carrageenin, linoleic acid and allantoin.

69. The process according to claim 65, wherein said proteins are selected from the group consisting of collagen, fibronectin, laminin, elastin, osteonectin, bone sialoprotein, alpha-2HS-glycoproteins, bone Gla-protein, matrix Gla-protein, bone phosphoglycoprotein, bone phosphoprotein, bone proteoglycan, protolipids, bone morphogenetic protein, cartilage induction factor, platelet derived growth factor, skeletal growth factor, proteins associated with cartilage, proteins associated with dentin, and proteins associated with enamel.

70. The process according to claim 53, wherein said inorganic liquid-phase mineral precursor is formed by combining calcium salt and said acidic polymer to form an aqueous solution, and reacting said aqueous solution with ammonium carbonate vapor.

71. The process according to claim 53, wherein said inorganic liquid-phase mineral precursor is formed by combining calcium chloride and a combination of acidic polymers to form an aqueous solution, and reacting said aqueous solution with ammonium phosphate vapor.

72. The process according to claim 53, wherein said inorganic liquid-phase mineral precursor is formed by combining calcium chloride and a combination of acidic polymers to form an aqueous solution, and reacting said aqueous solution with a phosphate containing solution.

73. The process according to claim 53, wherein said inorganic liquid-phase mineral precursor is formed by combining calcium salt and a combination of acidic polymers to form an aqueous solution, and reacting said aqueous solution with phosphate generated by enzymatic degradation of phosphate containing compounds.

74. The process according to claim 53, wherein said inorganic liquid-phase mineral precursor is formed by combining calcium salt and ammonium phosphate, and a combination of acidic polymers to form an aqueous solution, in which precipitation is caused by a change of temperature, pH, evaporation, or removal of crystallization inhibitor.

75. The process according to claim 53, wherein said process is carried out at a temperature of about 0°C to about 100°C.

76. The process according to claim 53, wherein said process is carried out at a temperature of about 37°C.

77. The process according to claim 53, wherein said process is carried out at a pH of about 5.0 to about 10.

78. The process according to claim 53, wherein said process is carried out at a pH of about 7.4.

79. The process according to claim 53, wherein said process is carried out at atmospheric pressure.

80. The process according to claim 42, wherein said fluid-swellable matrix comprises an exterior surface and an interior containing an interstitial space, wherein said inorganic liquid-phase mineral precursor is absorbed into said interstitial space of said fluid-swellable matrix, and deposited onto said exterior surface of said fluid-swellable matrix; and wherein said liquid-phase mineral precursor deposited onto said exterior surface of said fluid-swellable matrix has a non-faceted topography when solidified.

81. An organic/inorganic composite made according to the process of claim 53.

82. The organic/inorganic composite of claim 64, wherein said fluid-swellable matrix comprises a material selected from the group consisting of collagen, elastin, polyanhydride, polyorthoester, chitin, chitosan, polyphosphazene, polyactide, glycosaminoglycan, gelatin, and bioresorbable polymer sponge; and wherein said inorganic liquid-phase mineral precursor is selected from the group consisting of calcium phosphate, calcium carbonate, hydroxyapatite, strontium carbonate, calcium sulfate, calcium oxalate, magnesium-bearing calcium carbonate, and magnesium-bearing calcium phosphate, or combinations thereof.

83. The organic/inorganic composite of claim 81, wherein said inorganic mineral phase comprises at least one member selected from the calcium phosphate group consisting of hydroxyapatite, octacalcium phosphate, tricalcium phosphate, carbonated hydroxyapatite, fluorinated hydroxyapatite, brushite, magnesium containing hydroxyapatite, dicalcium phosphate dihydrate, and amorphous calcium phosphate.

84. A method for treating a bone defect comprising applying an organic/inorganic composite to the site of the bone defect, wherein said organic/inorganic composite comprises a fluid-swellable matrix and an inorganic mineral phase, and wherein said inorganic mineral phase is absorbed into said fluid-swellable matrix when said inorganic mineral phase is in the form of a liquid-phase mineral precursor, which subsequently solidifies.

85. The method according to claim 84, wherein said organic/inorganic composite is applied as an injectable liquid, a film, a malleable putty, a malleable paste, a particulate, or a molded or preformed solid.

86. The method according to claim 84, wherein said fluid-swellable matrix comprises a material selected from the group consisting of collagen, elastin, polyanhydride, polyorthoester, chitin, chitosan, polyphosphazene, polyactide, glycosaminoglycan, gelatin, and bioresorbable polymer sponge, polyacrylates, polylactic-co-glycolic acid (PLGA), polyester, polyether, polyorthoester, chitin, chitosan, polyphosphazene, polylactide, glycosaminoglycan, gelatin, biopolymers, and biocompatible and bioresorbable polymer sponge.

87. The method according to claim 84, wherein said inorganic mineral is selected from the group consisting of calcium phosphate, calcium carbonate, hydroxyapatite, strontium carbonate, and calcium sulfate, calcium oxalate, magnesium-bearing calcium carbonate, and magnesium-bearing calcium, or combinations thereof.

88. The method according to claim 84, wherein said organic/inorganic composite further comprises a biologically active agent.

89. The method according to claim 84, wherein said organic/inorganic composite is porous.

90. The method according to claim 84, wherein said organic substrate is biocompatible and bioresorbable.

91. The method according to claim 84, wherein said fluid-swellable matrix comprises a scaffold seeded with cells.

92. The method according to claim 91, wherein said cells are selected from the group consisting of bone marrow stem cells, osteoblasts, osteoclasts, osteocytes, blood cells, epithelial cells, odontoblast, ameloblasts, and neural cells, or combinations thereof.

93. The method according to claim 84, wherein said organic substrate comprises a film.

94. The method according to claim 84, wherein said organic/inorganic composite comprises a plurality of said fluid-swellable matrices arranged as laminae.

95. The method according to claim 94, wherein said lamellae are arranged concentrically around a central void for passage of endogenous or exogenous cells.

96. The method according to claim 84, wherein said organic/inorganic composite comprises a plurality of said fluid-swellable matrices, and wherein said organic/inorganic composite further comprises an adhesive layer between each of said organic substrates.

97. The method according to claim 96, wherein said plurality of organic substrates have a parallel orientation.

98. The method according to claim 96, wherein said plurality of organic substrates are in an alternating orientation.

1/10



FIG. 1A



FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A




FIG. 3B




FIG. 3C



FIG. 3D




FIG. 4A




FIG. 4B




FIG. 5A



FIG. 5B



FIG. 5C




FIG. 5D



FIG. 6A



FIG. 6B

FIG. 7A

FIG. 7B




FIG. 7C

FIG. 7D

4/10



FIG. 8A




FIG. 8B



FIG. 8C

5/10




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D

6/10




FIG. 10




FIG. 11



FIG. 12




FIG. 13



FIG. 14




FIG. 15





FIG. 16



FIG. 17A



FIG. 17B



Scaffold Type

FIG. 18




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 19D




FIG. 19E




FIG. 20A




FIG. 20B




FIG. 20C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/12076

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61L27/24 A61L27/44 A61L31/12 A61L31/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA, INSPEC, COMPENDEX

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 532 217 A (CHRISTIANSEN DAVID ET AL) 2 July 1996 (1996-07-02)</p> <p>column 2, line 5 - line 15 column 2, line 29 -column 3, line 2 example 1 claims 1-10</p> <p>---</p> <p style="text-align: center;">-/--</p>	<p>1-16, 20-36, 38-59, 62-69, 72,74-95</p>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

11 August 2003

Date of mailing of the International search report

01/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Menidjel, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/12076

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 273 964 A (LEMONS J E) 28 December 1993 (1993-12-28) column 1, line 13 - line 43 column 6, line 27 - line 68 column 7, line 1 - line 36 column 8, line 3 - line 51 column 12, line 9 - line 41 ---	1,4-12, 14, 20-36, 40, 42-46, 53-69, 72-92
X	KIKUCHI MASANORI ET AL: "Preparation of hydroxyapatite/collagen composites using biomimetic process and their biocompatibility" MATERIALS RESEARCH SOCIETY SYMPOSIUM PROCEEDINGS, MATERIALS RESEARCH SOCIETY, PITTSBURG, PA, US, vol. 599, 2000, pages 51-53, XP002960419 ISSN: 0272-9172 abstract page 51, paragraph 2 page 52, paragraph 2 - last paragraph page 53, last paragraph ---	1,2,4-8, 11-13, 20,21, 31-38, 44-46, 53-59, 62,63, 75-87, 90-92 1-98
Y	GOWER L B ET AL: "Deposition of calcium carbonate films by a polymer-induced liquid-precursor (PILP) process" JOURNAL OF CRYSTAL GROWTH, NORTH-HOLLAND PUBLISHING CO. AMSTERDAM, NL, vol. 210, no. 4, March 2000 (2000-03), pages 719-734, XP004191390 ISSN: 0022-0248 abstract page 724, right-hand column, paragraph 1 -page 726, left-hand column, paragraph 1 page 729, left-hand column, paragraph 1 -page 730, left-hand column, paragraph 2 ---	1-98
X	DATABASE COMPENDEX 'Online' ENGINEERING INFORMATION, INC., NEW YORK, NY, US; ROVERI N ET AL: "Biologically inspired growth of hydroxyapatite nanocrystals inside self-assembled collagen fibers" Database accession no. E2003097376637 XP002250940 abstract & MATER. SCI. ENG. C; MATERIALS SCIENCE AND ENGINEERING C MAR 3 2003, vol. 23, no. 3, 3 March 2003 (2003-03-03), pages 441-446, ---	1,53,84
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/12076

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 03 035127 A (JAPAN SCIENCE & TECH CORP ; ITO NORIICHI (JP); TANAKA JUNZO (JP); K) 1 May 2003 (2003-05-01) abstract -----	1-98

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 84-98 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/12076

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5532217	A 02-07-1996	US	5739286 A	14-04-1998
US 5273964	A 28-12-1993	NONE		
WO 03035127	A 01-05-2003	JP WO	2003190271 A 03035127 A1	08-07-2003 01-05-2003